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Abstract 
 
Systemic lupus erythematosus is the prototypical autoimmune disease characterised 
by multi-organ involvement. Genetic variance is one of the most potent risk factors for 
development of lupus yet currently identified variants only account for 15% of genetic risk. 
Despite a strong genetic basis it does not follow Mendelian patterns of inheritance. A 
favoured hypothesis is that many common, mildly damaging variants combine to predispose 
to lupus. An alternative hypothesis is that few rare damaging variants cause disease. Single 
nucleotide and copy number variation have both been increasingly associated with a diverse 
range of diseases and this thesis investigates their contribution to lupus in isolation or in 
epistasis. 
 
This thesis describes the use of whole exome sequencing and SNP-chip arrays to 
identify genetic variants that associate with systemic lupus erythematosus. Using a 
combination of molecular tools we demonstrate the translational consequences of these 
variants and how the alterations to protein function may then disturb cellular function. In the 
final step of proof of causation we generate bespoke mouse models of the variants to 
demonstrate and test the effect of these variants in autoimmunity. Specifically we show that 
inheritance of a rare damaging mutation in BANK1 together with a second damaging rare 
mutation in one of three BANK1-interacting proteins: BLK, SAMSN1 or IRAK2, alters B cell 
responses to TLR ligands increasing secretion of the lupus-promoting cytokines IL-6 and IL-
10. Introduction of the human BANK1W40C, BLKR131W and SAMSN1T198A variants in mice via 
CRISPR/Cas9 reveals the mutant alleles increase IL-6 production by B cells and cause 
lupus-like disease. These results provide support for digenic or oligogenic lupus, bespoke 
mouse models of human lupus, and novel targets for personalised intervention. 
 
Using a SNP-chip array a large intronic deletion in VANGL1 was identified that 
associated with glomerulonephritis in a cohort of SLE. Kidneys from Vangl1 deficient mice 
 vi 
 
demonstrated spontaneous IgA and IgG deposition but were normal by light microscopy, 
with no evidence of systemic autoimmunity. B cell deficient Vangl1 mice, but not B cell 
sufficient Vangl1 mice, injected with wild type or Vangl1+/- serum demonstrated IgG 
deposition indicating a kidney intrinsic mechanism for the development of nephritis. 
 
 This thesis identifies and demonstrates the contribution of rare single nucleotide 
variants functioning in systemic autoimmunity. The demonstration of the oligogenic 
contribution is a first for complex autoimmunity, as are many of the interactions and 
consequences of the mutations. Further, this thesis identifies genetic mechanisms through 
which organ-specific manifestations of lupus may occur – relatively common copy number 
variants in VANGL1 associates with increased risk of lupus nephritis.  
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Systemic Lupus Erythematosus 
 
Systemic lupus erythematosus is a chronic, debilitating relapsing and remitting 
autoimmune disease. The clinical presentation of lupus is highly heterogeneous, resulting in 
the establishment of the 11 criteria of which 4 were required to meet the formal diagnosis of 
SLE[1]. Prevalence rates range from 20 to 150 per 100,000 and follows clear racial and 
gender predilections [2]. The mainstay of modern therapy is non-specific anti-proliferative 
agents and the promise of targeted monoclonal antibodies such as anti-B cell activating 
factor (BAFF) and anti-CD20 antibodies have largely failed in randomised clinical trials [3] 
Phase III RCTs that led to approval of anti-BAFF antibodies (belimumab) for SLE reported 
highly conditional benefits; only at 52 weeks of therapy and not 76, only at higher doses and 
only for the Systemic Lupus Erythematosus Responder Index (SRI) and other measures of 
disease activity [4,5]. This may relate to the growing realisation that, like clinical 
presentation, the underlying pathophysiology of SLE is equally heterogeneous with 
complement, T, B and myeloid cell biology, and cytokine-based mechanisms all being 
significantly implicated in the disease process. Additionally, environmental and other risk 
factors including hormonal influences contribute to induce dysregulation of the immune 
system.  
 
1.1 Systemic lupus erythematosus – Historical context and presentation 
 
The attribution of lupus, Latin for wolf, to SLE was due to the destructive cutaneous 
lesions that were reminiscent of bites from this animal. The earliest descriptions of SLE were 
by Hippocrates, detailing cutaneous ulcerations as herpes esthiomenos (gnawing 
dermatosis). Although described in various forms, the first clear description of lupus 
erythematosus is credited to Laurent Biett [6] of the Paris School of Dermatology. His 
student, Pierre Louis Cazenave, coined the term “lupus erythematosus” and described lupus 
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as a rare skin condition, appearing most frequently in young females and primarily involving 
the face [7]. Both Moriz Kaposi [8] and William Osler [9], who possibly coined the term 
“systemic lupus erythematosus”, built upon these early descriptions to conceptualise lupus 
as a systemic auto-inflammatory disease affecting multiple organs. 
 
This historic difficulty in studying SLE arises from its rarity and heterogeneous 
presentation. Virtually any organ system may be affected by SLE, ranging from mild 
cutaneous lesions to kidney failure. The most common manifestations are cutaneous 
lesions, arthritis and blood or serological abnormalities [10]. Although these have profound 
adverse effects on quality of life, with the exception of the lupus anticoagulant these also 
contribute the least to the mortality burden in SLE. Kidney involvement, particularly end-
stage kidney disease, is one of the most potent risk factors for death [11]. Neurological and 
cardiac disease are also poor prognostic manifestations [12] and some extractable nuclear 
antigen antibodies are reportedly associated with superior outcomes [11].  
 
In 1971, in an effort to unify observations of SLE, a consensus criterion was 
established to standardise the diagnostic definition of SLE based upon the descriptions by 
Osler, Kaposi and others. In 1982, advances in serological testing (anti-nuclear and anti-
double-stranded deoxyribonucleic acid (DNA) antibodies) and biostatistical techniques led to 
a revision of these criteria; the American College of Rheumatology (ACR) revised diagnostic 
criteria which are used to this day [1]. The ACR criteria defines the syndrome of SLE as 
requiring 4 or more of 11 clinical or serological diagnostic criteria (Table 1) and was 
designed as a standard to facilitate research. Several iterations have been proposed since; a 
modest revision in 1997 by Hocheberg [13] adding antiphospholipid antibodies, the 2012 
Systemic Lupus International Collaborating Clinics (SLICC) Classification criteria where 
clinical and laboratory criteria are categorised separately and requiring a combination of 
clinical and immunologic criteria [14].  
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Table 1. 1997 Update of the American College of Rheumatology revised criteria for 
classification of systemic lupus erythematosus 
Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
Discoid rash Erythematous raised patches with adherent keratotic scaling 
and follicular plugging; atrophic scarring may occur in older lesions 
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history 
or physician observation 
Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by 
physician 
Non-erosive 
arthritis 
Involving 2 or more peripheral joints, characterized by tenderness, 
swelling, or effusion 
Pleuritis or 
pericarditis 
1. Pleuritis--convincing history of pleuritic pain or rubbing heard by 
a physician or evidence of pleural effusion 
OR 
2. Pericarditis--documented by electrocardiogram or rub or 
evidence of pericardial effusion 
Renal disorder 1. Persistent proteinuria > 0.5 grams per day or > than 3+ if 
quantitation not performed 
OR 
2. Cellular casts--may be red cell, haemoglobin, granular, tubular, 
or mixed 
Neurologic 
disorder 
1. Seizures--in the absence of offending drugs or known metabolic 
derangements; e.g., uraemia, ketoacidosis, or electrolyte 
imbalance 
OR 
2. Psychosis--in the absence of offending drugs or known 
metabolic derangements, e.g., uraemia, ketoacidosis, or 
electrolyte imbalance 
Chapter 1: Introduction 
 
5 
 
Hematologic 
disorder 
1. Haemolytic anaemia--with reticulocytosis 
OR 
2. Leukopenia--< 4,000/mm3 on ≥ 2 occasions 
OR 
3. Lymphopenia--< 1,500/ mm3 on ≥ 2 occasions 
OR 
4. Thrombocytopenia--<100,000/ mm3 in the absence of offending 
drugs 
Immunologic 
disorder 
1. Anti-DNA: antibody to native DNA in abnormal titre 
OR 
2. Anti-Sm: presence of antibody to Sm nuclear antigen 
OR 
3. Positive finding of antiphospholipid antibodies on: 
1. an abnormal serum level of IgG or IgM anti-
cardiolipin antibodies, 
2. a positive test result for lupus anticoagulant using a 
standard method, or 
3. a false-positive test result for at least 6 months 
confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test 
Positive 
antinuclear 
antibody 
An abnormal titre of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs 
Chapter 1: Introduction 
 
6 
 
 
The ACR criteria helped estimate the incidence and prevalence of SLE. It was 
observed that race and gender not only predispose to SLE, but also influence the types and 
calibre of organ involvement [15,16]. Incidence rates range from 1 to 10 per 100,000 person-
years and prevalence rates generally range from 20 to 70 per 100,000 [17,18]. Asian or 
African-American populations have significantly higher incidence and prevalence rates of 
SLE than those of other racial backgrounds [16]. Almost universally these epidemiological 
studies identified a potent predisposition to SLE in women with a female-to-male ratio of 9:1. 
Initially typified as affecting women of childbearing age after epidemiological studies 
performed in the United States (US), this observation has since been proposed to be derived 
from strong racial influences; namely, that SLE is more common in African-American women 
of childbearing age, but not other racial backgrounds [19]. 
 
This racial predisposition also influences prognosis. Historically, prior to the ACR 
criteria and introduction of corticosteroids, the 5 year mortality was below 50% [20].  
Advances in diagnosis and treatment have improved 5-year survival rates to approximately 
95% [20]). Despite these improvements, however, standardised mortality rates are still 2-4 
times higher than the general population [21]. Five-year survival varies globally: Whereas 
European and North American countries report 5-year survival rates of approximately 95%, 
countries with lower socio-economic status have published 5-year survival rates of 57-86% 
[22-25] likely relating to disparities in health service, education, and availability of resources 
considered standard in North America and Europe. It has been reported that American SLE 
patients of African descent have 3 times higher mortality, and SLE patients of Asian descent 
had 1.8 to 2.7 times higher mortality, than Americans of European descent [26]. Importantly, 
it is also observed that the higher mortality risk observed between races crossed health 
insurance strata suggesting access to health services did not account for this difference [27]. 
A possible explanation is differing disease manifestations between these racial groups; 
namely, that those of African American and Asian ancestry are more likely to have kidney 
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involvement, and kidney involvement is the most consistent and potent predictor of mortality 
[28]. Together, these studies implicate racial background in strongly influencing 
development, disease manifestation and prognosis of SLE. 
 
The large scale clinical trials following adoption of the ACR criteria led to several 
advances in the treatment of SLE.  Development of anti-proliferative immunosuppressants 
such as azathioprine and mycophenolate, which inhibit purine synthesis and prevent 
lymphocyte proliferation, translated into significant improvements in mortality. Modern 
therapy ranges from anti-proliferative medications such as hydroxycholoroquine, 
azathioprine and mycophenolate to potent, toxic alkylating agents such as 
cyclophosphamide. These agents are often adjuvants to minimise use of corticosteroids, 
powerful immunosuppressive agents with equally profound side-effects including increased 
risks of infection, malignancy, osteoporosis, insulin resistance, and Cushing’s syndrome. 
Whilst certain agents may be superior for particular disease manifestations (i.e. 
mycophenolate for classes of lupus nephritis [29]) the common theme unifying modern 
immunosuppressive agents is that they non-specifically suppress the immune system. 
 
The age of “biological agents”, monoclonal antibodies directed against specific 
moieties, promised greater precision in therapy. The term “biological agent” refers to the first 
generation agents which were antibodies raised against specific epitopes, such as Tissue 
Necrosis Factor (TNF) or cluster of differentiation (CD) 19. These epitopes, expressed on 
specific lymphocytes or part of particular inflammatory processes, represented precise 
targets for intervention. Targets trialled in SLE include CD20 and B-Cell Activating Factor 
(BAFF). However, the agents most promising in concept and murine trials such as the B cell 
suppressing anti-BAFF [30] and B cell depleting anti-CD20 [31] antibodies have been found 
to be mildly or not superior to current treatment for the majority of SLE and are only 
anecdotally successful in cases of SLE resistant to conventional treatment. This 
disappointing realisation is likely due to the either the highly complex pathophysiology of 
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SLE wherein virtually all limbs of the immune system may be dysregulated in any one 
individual, or the heterogeneity in disease pathogenesis between individuals. If the latter is 
true, lupus may be a collection of different diseases that present with shared clinical 
manifestations but are caused by different molecular pathways. Monoclonal antibodies 
against particular cells or cell products may thus only be effective in the subset of patients 
with a molecular dysregulation that can be targeted by the antibody. 
 
1.2  Overview of the immune system 
 
The immune system is a highly evolved and specialised group of defence 
mechanisms responsible for protecting individuals from foreign pathogens. It is composed of 
two broad and linked limbs, the innate and adaptive immune systems. Innate immunity is 
typified by non-specific defence mechanisms such as physical barriers of the skin, or flow of 
urine and tears. It also includes leukocytes such as myeloid cells, natural killer cells and 
innate lymphoid cells, capable of recognising and responding to generic foreign compounds. 
These include lipopolysaccharide (a component of bacterial endotoxin) and viral or bacterial 
DNA. Innate cells present this foreign antigen in the presence of additional stimulatory 
signals to members of the adaptive immune response. Adaptive immunity is mediated by T 
and B cells and in comparison to the innate, is capable of recognising specific individual 
pathogens or antigens and generating increasingly potent and precise responses to that 
pathogen. Further, after refining immunological responses it is capable of preserving that 
response through long-lived immunological memory – the principle of vaccination. 
 
Antigen, a term for any compound capable of inducing an antibody response is 
typically part of the invading pathogen. Innate leukocytes such as macrophages or dendritic 
cells, also referred to as antigen presenting cells (APCs), are capable of recognising, 
ingesting and processing foreign particles and apoptotic cells within specialised organelles – 
endosomes and lysosomes. The digested material is then presented by APCs complexed 
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with major histocompatibility complex (MHC), a protein responsible for regulating recognition 
of self-tissue. Material originating from outside the cell is processed into small peptides 
which are presented on MHC-II; foreign material originating from inside the cell is presented 
on MHC-I [32]. Dendritic cells can also present extracellular material on MHC-I in a process 
known as cross-presentation [33]. APCs migrate to secondary lymph organs, such as lymph 
nodes, tonsils, or Peyer’s patches, where they present antigen to T cells that bear specific 
receptors for the peptide presented on MHC molecules. 
 
T (from thymus) cells are a class of lymphocytes which originate as lymphoid 
precursors in the bone marrow before migrating to the thymus. There, they undergo a 
process of positive selection where the T cell receptor (TCR) is selected to recognise self-
MHC. After positive selection, the TCR is then tested for recognition of self-tissue and T cells 
binding self-peptide-MHC with high affinity become regulatory T cells, or undergo negative 
selection by apoptosis, a process of programmed cell death [34]. After this dual selection, T 
cells circulate as naïve cytotoxic CD8+ or helper CD4+ T cells. When the naïve T cell 
encounters antigen specific to its TCR, presented by APCs and with appropriate co-
stimulation by CD80/CD86 expressed on APCs, it is activated. Cytotoxic CD8+ T cells 
recognise antigen presented on MHC I, whereas helper CD4+ T cells recognise antigen 
presented on MHC II. In the case of either CD4+ or CD8+ T cells, recognition by the TCR 
combined with appropriate co-stimulatory signals results in differentiation into either an 
effector or memory T lymphocyte [32]. Of the CD4+ helper T cell class, there are an 
expanding number of recognised subsets including T helper 1, T helper 2, T helper 17, T 
follicular helper and T regulatory cells [35]. Each promotes immune responses against 
particular types of pathogen through secretion of specialised cytokines and through cell-cell 
interactions. Ultimately, CD4+ helper T cells help activate macrophages (Th1), eosinophils 
(Th2),  neutrophils (Th17) and B cells (Tfh) to respectively fight infections by intracellular 
bacteria and viruses, helminths, fungi and extracellular bacteria and viruses. 
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B (from bursa) cells are the other major class of lymphocyte. Like T cells, they are 
derived from bone marrow haematopoietic stem cells [36] and express an antigen 
recognising receptor, the B cell receptor (BCR). The BCR is composed of heavy and light 
immunoglobulin chains, with an antigen-binding fragment (Fab) composed of variable(V), 
diversity(D) and joining(J) segments; the random combination of these components 
constitutes the diversity of the BCR for antigen. The Fc fragment of the secreted 
immunoglobulin is bound by Fc receptors present in effector immune cells.  
 
B cells emerge from the marrow into peripheral circulation and secondary lymphoid 
organs as transitional B cells, which may be subdivided into transitional 1 (T1), transitional 2 
(T2), and transitional 3 (T3) B cells [37]. These transitional B cells differentiate into mature-
naïve B cells which divide rapidly in response to antigen [38]. B cell receptor engagement 
and B cell costimulation through cell-surface CD19 and CD21 stimulate activation and 
differentiation [39,40]. Activated B cells receiving T cell help in secondary lymphoid organs 
may then become germinal centre (GC) B cells which proliferate and class-switch the BCR 
constant region from IgM/IgD to another isotype of IgG, IgA, or IgE [41]. A proportion of 
these may differentiate into antibody secreting cells (plasmablasts or plasma cells) or 
memory B cells which may rapidly respond to re-exposure to cognate antigen [37]. Typical 
flow cytometric markers of these stages of development are listed in Table 2. 
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Table 2. Surface phenotype defined human peripheral B subsets.  
Name Type Phenotype 
Transitional B cell T1 IgD+CD27negCD10+ 
CD24HiCD38Hi 
 T2 IgD+CD27negCD10+ 
CD24Hi/+CD38Hi/+ 
 T3 IgD+CD27negCD10neg 
CD24+/lowCD38+/low 
Mature Naïve B cell  IgD+CD27negCD10neg 
CD24+/lowCD38+/lowMTGneg 
Memory Double negative IgD+CD27neg 
 Non-switched IgD+CD27+ 
 IgM-only IgM+IgD+CD27+ 
 Switched IgMnegIgDnegCD27+ 
Antibody secreting cell Plasmablast IgMnegCD27hi 
CD38hiCD138neg 
 Plasma cell IgMnegCD27hi 
CD38hiCD138+ 
(Adapted from Kaminski et al.)[37] 
 
B cells are also selected during their development to limit self-reactivity. In the bone 
marrow, B cells recognising self-antigen undergo deletion, receptor editing or become 
anergic [42,43]. Nevertheless, the mechanisms ensuring self-tolerance for B cells, however, 
are not as robust as for T cells since immature B cells leaving the bone marrow contain a 
significant fraction of self- or polyreactive B cells [44]. Further tolerance checkpoints operate 
at the point of selection into the mature recirculating follicular repertoire to purge a significant 
fraction of these self-reactive B cells. Amongst them is competition for BAFF, for which 
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anergic B cells are less responsive [45,46]. Additional checkpoints operate in the periphery 
after B cell activation by protein antigen, including the need for co-stimulation through CD40 
from rigorously self-tolerised T cells [46] which recognise the cognate antigen that has 
activated the B cell, and potentially mutation away from self-reactivity within germinal centres 
[47] followed by stringent selection by limiting follicular helper T cells [48].   
 
B cells do have the capacity to activate independently of T cell assistance in 
response to T cell-independent antigens, but unlike T-dependent responses, these antigens 
mainly induce extrafollicular B cell differentiation (see below) and thus do not typically induce 
long-lived antibody responses. Nevertheless, evidence from animal models suggests that 
these extrafollicular responses may become longer-lived and pathogenic in the context of 
inflammation. T-independent antigens include those capable of extensive BCR crosslinking 
with antigen multimers or those capable of delivering toll-like receptor (TLR) stimulation [49]. 
TLRs are a class of receptors expressed primarily in myeloid cells and B cells which 
recognise pathogen-associated molecular patterns (PAMPs) [50]. PAMPs are typically core 
components of foreign pathogens such as lipopolysaccharide from endotoxin (recognised by 
TLR4), RNA (recognised by TLR7 and TLR8) or viral and bacterial DNA (recognised by 
TLR9). Ultimately, engagement of TLR or BCR may induce the B cell to either rapidly 
differentiate into short-lived plasmablasts capable of producing a soluble form of the BCR 
called immunoglobulin (Ig) [51], which is of limited affinity for the antigen, or to enter the 
follicle in secondary lymph organs to enhance the affinity of the BCR for the antigen. Within 
the lymphoid follicle, a specialised structure called the germinal centre forms when T 
follicular helper (Tfh) cells and their cognate B cells migrate into the centre of the follicles.  
There, the now called germinal centre B cells undergo rapid expansion and a process called 
somatic hypermutation(SHM), wherein random mutation edits the BCR resulting in 
stochastic increases and decreases in affinity [52]. The process may also induce 
autoreactive autoantibodies. Selection by limiting Tfh cells promotes competition between B 
cells for survival signals, so those capable of presenting more antigen to T cells – and thus 
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expressing higher affinity receptors – are selected. It is thought that Tfh cells and possibly T 
follicular regulatory (Tfr) cells that derive from Tregs, represent a tolerance check-point and 
may prevent selection or promote death of B cells that have acquired self-reactive receptors 
through SHM.  
 
The complement system is an intricate network of effectors, receptors and regulators 
that are involved primarily in opsonisation, clearance of cellular debris and apoptotic cells, 
and recognition of foreign microbes. In these roles it is involved in both innate and adaptive 
responses, and dysregulation of several of its diverse functions has been implicated in SLE 
pathogenesis. Complement has a significant role in removing immune complexes from the 
circulation, achieved by the binding of complexes to the complement receptor 1 (CR1) 
expressed on erythrocytes. There are three main pathways to activation of complement; the 
classical pathway which is antibody dependent, the lectin pathway mediated by mannose-
binding lectin (MBL), and the alternative pathway mediated by ‘tickover’ of C3 [53].  
 
The classical pathway is strongly initiated by IgM/IgG clusters but the pattern 
recognition molecule C1q also activates complement by recognising distinct structures 
directly on microbial and apoptotic cells. The C1 complex consists of C1q bound to C1r and 
C1s, with bound C1s cleaving C4 into C4a and C4b, and cleaving C4b-bound C2 into C2a 
and C2b – resulting in formation of C4b2b, the classical pathway C3 convertase. The lectin 
pathway similarly uses assembly of MBL–associated serine proteases that are structurally 
similar to C1r/C1s to similarly cleave C4 and C2 to generate the CP C3 convertase C4b2b.  
 
In contrast to both the lectin and classical pathways, the alternative pathway 
represents three distinct but partially overlapping processes. First, a small fraction of the 
relatively inert C3 is hydrolysed to C3H20 which binds factor B (fB) and is in turn cleaved by 
factor D (fD) resulting in an initial solvent-based C3 convertase (C3H20Bb) that activates 
complement by cleaving C3 into active components C3a and C3b. This cleavage exposes a 
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reactive thioester in C3b which is quickly amplified by foreign cells but regulated by human 
cells - the ‘tick-over’ phenomena. This positive feedback loop can rapidly amplify a 
complement response. The alternative pathway also includes a PRM-based initiation 
mechanism wherein properdin recognises several pathogen and damage-associated 
molecular patterns that allows recruitment of C3b to recognised surfaces and allows C3b 
convertase assembly [53]. All C3b convertase complexes can induce amplification of the 
alternative pathway via activation of C3. Furthermore, although named the alternative 
pathway it accounts for 80-90% of total complement activation [54]. 
 
Figure 1. The classical, alternative, and lectin pathways for complement activation[55] 
 
1.3  Pathophysiology of SLE 
 
Almost all components of the innate and adaptive immune systems have been 
implicated in the development of SLE. Despite being classically considered a disease based 
on B cell production of auto-antibodies, abnormalities have also been reported in not just B 
cell biology, but T cell biology, complement activation, uptake of apoptotic cells by 
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macrophages, neutrophil nets, autophagy, post-translational antigen modifications, DNA 
repair and cytokine signalling. Many of these pathways, however, may ultimately be 
implicated in inducing B cells to break tolerance through excessive or altered auto-antigen 
production, presentation, TLR or cytokine-mediated costimulation, or T cell help.  
 
1.3.1 Complement in SLE 
 
Several observations implicate complement strongly in SLE pathogenesis. First is the 
characteristic finding of complement deposition in organs with SLE involvement. For 
example, SLE nephritis is typified by a “full house” of immunological deposition with IgG, IgA, 
IgM and both C3 and C1q. Secondly, serum complement levels are often perturbed during 
active and quiescent disease and extensive work has attempted to determine the use of 
these fluctuations in predicting disease flare [56]. Typically, levels of classical pathway 
components (C4, C2) are low but, especially in patients with severe disease, may also be 
accompanied by a reduction in C3 levels. However, in some individuals C4 may remain low 
even when the patient is well [57]. It has been proposed that a panel of complement 
activation products – C1r, C1s, C1 inhibitor, and C4a-d (classic), Bb (alternative), and C3a-d, 
C5a, and C5b-9 (terminal complement complex) – may be superior to C3 or C4 alone.  In 
early studies elevated C3a, but not C5a, were seen in patients with more active disease and 
rises in C3a preceded flares in ~40% [58], though in inactive/stable disease C4d may be a 
more sensitive marker of subsequent flares [59]. However, for disease activity scores, 
elevation of C5b-9 had the strongest correlation with disease activity [60,61]. Ultimately the 
imprecise correlation between these various complement factors and disease activity limits 
their clinical utility. 
 
Third and most strikingly, genetic complement factor deficiency strongly predisposes 
to SLE. Deficiencies of the factors in the classical pathway, such as C1r, C1s, C4 and C2 
are associated with development of SLE and SLE-like disorders but not autoimmune disease 
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in general (i.e. rheumatoid arthritis (RA) and Sjogren’s syndrome (SS)). Further, deficiency 
of C1q, C1r/C1s or C4, but not C2, have equal male-female incidence and disease usually 
starts earlier in life than sporadically-occurring SLE. C1q deficiency and C1r/C1s deficiency 
are associated with a very high risk of developing disease whilst C4 and C2d deficiency 
have lesser risk (90% and 20%, respectively) [62]. Less than 70 cases of C1q deficiency 
have been reported, but all patients develop SLE [63] and in one case study bone marrow 
transplantation ameliorated SLE in a patient with C1q deficiency [64]. The correlation 
between deficiency of C1q and development of a disease process mediated in large part by 
complement is paradoxical but is thought to be related to impaired clearance of apoptotic 
debris. C1q has also been suggested to ensure the ‘silent’ removal of apoptotic cells by 
preventing ‘inflammasome’ assembly [65,66]. Additionally, C1q antibodies are a common 
observation in SLE; resulting decreased C1q levels may mimic a C1q deficient state. These 
antibodies have been proposed as a predictive marker for LN [67,68].  
 
C2 deficiency is found in around 1 in 20000 and increases the risk of infection and 
SLE with antibodies against C1q and cardiolipin [69] and a 28 base pair (BP) deletion in C2 
was found to be overrepresented in SLE patients of European descent [70]. Complete C4 
deficiencies are rare but CNV of C4 is common and the degree of expression affects plasma 
levels [69]. C4A, but not C4B, CNV are associated with SLE although the predisposition is 
likely to be modified by HLA haplotypes [71] as C4A is deleted in the extended haplotype 
HLAA1, B8, DR3 which is common in Caucasians and even more common in SLE [72] as 
are HLA CW-, C4*B1, C2*C, B*fS. C4A and C4B are two tandemly duplicated genes in the 
class III MHC region and are highly polymorphic with variants including non-expressed or 
null alleles (such as C4AQ*0 and C4BQ*0). C4AQ*0 has strong association with SLE in 
Caucasians [73] with SLE risks of 9.7 – 16.8 [74,75]. A C2 null C2Q*0 typically occurs in 
association with the haplotype HLA-A25, B18, CW-, DR2, C4A*2, C4B*2, Bf*s [76]. 
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In comparison, alternative pathway and terminal sequence deficiencies are all 
associated with increased risk for Neisserial infection but not SLE. Deficiency of C3 
associated with a high frequency of recurrent infection and an immune complex 
manifestation like GN observed in a post infectious background. There is no evidence linking 
genetic deficiency in MBL in SLE. 
 
Complement inhibitor mutations, such as in CFH, are found in numerous kidney 
diseases such as atypical haemolytic uraemic syndrome but weaker associations with SLE 
have also been made[63]. CR3 polymorphisms have been associated with SLE with a 
nonsynonymous allele observed to reduce phagocytic abilities of macrophages, neutrophils 
and monocytes with no difference in CR3 expression, cell migration or release of 
inflammatory markers [77]. 
 
Complement also plays an important role in directing B cell-mediated SLE processes. 
Complement is involved with presentation of antigen to B cells and it has been proposed that 
complement deficiency may result in less exposure of autoantigens to B cells with a 
corresponding reduction in tolerisation by these same B cells [78]. This theory proposes a 
protective role for complement in systemic lupus erythematosus and could in part explain 
how complement deficiencies would have strong associations with SLE. Locally produced 
C4 is also directly involved in the negative selection of autoreactive B cells by inducing 
anergy and C4-/- mice produce more autoreactive B cells [79]. Much of this signalling is 
mediated through the complement receptor 2 (CR2) which is expressed on B cells and CR2 
expression is altered in B cells of SLE patients. 
 
In aggregate, observations in human SLE suggest that complement deficiency 
predisposes to SLE. There are three main hypotheses: Firstly, that CP deficiency results in a 
reduced capacity for immune complex handling with reduced C1q and C4 in SLE 
accompanied by decreased density of complement receptor CR1 (CD35) on erythrocytes 
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[80]. Antibody binding to CR1 is an important mechanism for clearance of immune 
complexes which trigger inflammatory responses. However, polymorphisms causing CR1 
repression do not predispose to SLE [81]. Secondly, waste disposal hypothesis proposes 
that the main source of auto-antigen in SLE is apoptotic cells and several proteins play a role 
in scavenging of apoptotic cells, such as C1q together with CRP and natural IgM. 
Complement deficiency results in excess apoptotic cellular debris overwhelming clearance 
mechanisms [53]. Three, aberrant tolerance induction proposes that complement is required 
for elimination of self-reactive lymphocytes during maturation of the immune system and 
self-antigens are normally coated with complement fragment and delivered to specific B cells 
by binding to CR1 (CD25) and CR2 (CD21). Loss of this process of tolerisation against self-
antigen will impair elimination of self-reactive B cells [53]. 
 
1.3.2 B cells in SLE 
 
The characteristic feature of SLE is the production of auto-antibodies against nuclear 
complexes. Autoantibody production may be reflective of abnormal B cell activation and 
differentiation that is characteristic of both human lupus and murine models of SLE [82], 
and/or or may also reflect a defined breach in tolerance by which self-reactive B cells are not 
properly tolerised or anergy is selectively broken. B cell generation occurs continually 
throughout adult life and is subject to several tolerance checkpoints, defects in which may 
predispose towards autoimmunity. These may be grouped into central tolerance 
checkpoints, tolerance occurring during B cell development, or peripheral tolerance 
checkpoints, mechanisms controlling auto-reactivity after B cells have developed[83].  
 
In the bone marrow, B cells develop from stem cells through precursor stages, pro-B 
cell expressing immunoglobulin heavy chain (Igµ) to pre-B cell which express a pre-BCR 
complex comprised of Igµ, surrogate light chains, and two signal-transducing proteins Igα 
and Igβ. The pre-BCR and IL-7 receptor promote survival of the pre-B cell until 
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downregulation of the pre-BCR. Rearrangement of the light chain leads to expression of a 
BCR and therein developing diverse antigen specificity in the B cell compartment. Random 
rearrangement of V(D)J segments in the BCR results in vast numbers of antigens 
recognised by B cells. The stochastic nature of V(D)J rearrangement that leads to such vast 
receptor diversity also results in creation of a large number of autoreactive B cells [44]. Even 
though these auto-reactive B cells can be detected at an early stage in B cell development, 
they are largely suppressed through deletion, anergy, or receptor editing [44,84].  
 
Clonal selection was first proposed by Burnet in the 1950s, postulating that self-
reactive lymphocytes were eliminated to prevent immune responses against self [85]. 
Subsequently it was shown in transgenic mouse models of B cells that when immature B 
cells react with a self-antigen with high avidity, such as a highly expressed membrane-bound 
protein, B cell differentiation arrests and the B cell undergoes apoptosis within 2 to 3 days 
[86,87]. Low affinity interactions permitted further differentiation but also a shorter lifespan 
resulting in deletion in the periphery [84]. However, it also became apparent that clonal 
deletion was the fall back after failure of receptor editing to induce tolerance. 
 
In the early 1990s three papers proposed that the immune system could remove 
antibodies reacting with high affinity to self antigen whilst preserving the cells that produce 
their specificities [88-90]. In transgenic mouse models against specific antigen, autoreactive 
immature B cells were shown to ‘edit’ their antigen receptors away from auto-reactivity. In 
this program, autoreactive immature B cells reactivate immunoglobulin rearrangement 
processes resulting in expression of a new light chain that pairs with the existing heavy chain 
to for a new, non-autoreactive BCR. Therein, the B cell is capable of being selected to the 
periphery. Depending on the avidity of the BCR for self-antigen, editing B cells can 
completely down-modulate surface expression of IgM (and resemble pre-B cells) or express 
low to normal levels of sIgM [91,92]. So efficient is this process that, based on chimeric 
studies of autoreactive B cell mouse models, autoreactive B cells with or without their self-
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antigen are capable of producing a normal B cell population[93]. Indeed, partial or complete 
inhibition of receptor editing programs results in defaulting to clonal deletion, with marked 
reductions or absence of B cell development [93]. 
 
 Despite the significant fraction of self-reactive B cells leaving the bone marrow as 
transitional B cells, a large proportion of these cells are purged from the mature recirculating 
follicular repertoire [44]. One of such mechanisms is anergy, causing reduced ability to 
compete for limited BAFF. BAFF is a homotrimer that was discovered by several groups as 
part of a concerted search for members of the TNF superfamily [94-96] that arose based on 
increasing recognition of the role of TNF receptors and their ligands in regulation of 
lymphocyte survival [97,98]. BAFF is found either on the cell surface as a type II 
transmembrane protein or is released in a soluble form after cleavage. It is produced by 
macrophages, monocytes, and dendritic cells in response to IFN-y [94,95,99] and IL-10 [99]. 
BAFF has structural similarities to APRIL, a proliferation-inducing ligand, and these ligands 
may share several biological activities [100,101]. BAFF binds to three separate receptors – 
BCMA (B-cell maturation antigen), TACI (transmembrane activator and calcium-modulator 
and cyclophilin ligand) and BAFF-R (BAFF receptor) [102]. These three receptors have 
different expression profiles; BCMA is expressed on mature B cells and plasma cells 
[103,104], TACI on B cells and a subset of activated T cells [105,106], and BAFF-R which is 
restricted to B cell lineages [106]. Whilst APRIL shares TACI and BCMA as receptors with 
BAFF, BAFF-R is selectively ligated by BAFF [106,107].  
 
BAFF is important in the maturation of B cells. After migrating from the bone marrow 
to the spleen, immature B cells pass through two transitional stages – transitional type I (T1) 
and transitional type II (T2) - before differentiating into naïve mature B cells [108], although 
very few make this transition [109]. BAFF-deficient mice have impaired T1 – T2 maturation 
[110,111] as does induced BAFF inhibition [111] as evidenced by normal T1 populations in 
these mice but no T2 [110,111]. It has been postulated that BAFF may induce transitional B 
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cells to overcome apoptotic (clonal deletion) signals triggered through the BCR [102]. To 
support this is evidence that Baff-transgenic mice express higher levels of the anti-apoptotic 
protein Bcl-2 than wild-type mice and develop autoimmune disorders similar to Bcl-2 
transgenic mice [112-114]. BAFF prolongs the survival of T2 B cells and all mature B-cell 
subsets in the periphery, regardless of whether they are resting or activated [115,116]. When 
BAFF is overexpressed, T2 and marginal zone B cells are increased [114] and the reciprocal 
phenotype is observed in BAFF deficiency [110,111]. Furthermore, BAFF may potentiate 
antibody responses and increase the number of plasma cells [115,117], as well as 
increasing serum immunoglobulin in the blood [117], particularly IgA [115]. 
 
Therefore, although essential to B cell homeostasis, BAFF is also strongly associated 
with autoimmunity. Overexpression in mouse models induces B cell hyperplasia, elevated 
serum immunoglobulins, autoantibodies and renal involvement reminiscent of SLE [114,118] 
as well as exocrine autoimmunity reminiscent of Sjogren’s Syndrome [114]. Marginal zone B 
cells are a prominent phenotype of the BAFF-transgenic mice, and this phenotype is a T cell 
independent phenomena [119]. It appears this process is a B cell intrinsic phenomena and is 
driven by TLR7/9 stimulation [119]. In NZB/W mice a marked autoreactive population in T2 
and MZ B cells is observed [116,120] and the marginal zone compartment is implicated in 
oestrogen-induced models of autoimmunity [121]. In human disease, such as RA and 
Sjogren’s syndrome an association was found between elevated BAFF in the blood and 
severity of disease [122,123]. The strongest evidence for the importance of BAFF is the 
discovery that competition for BAFF is used to induce anergy in autoreactive B cells [45] and 
is therefore a mechanism through which therapeutic inhibition has been shown to be of 
some benefit.  
 
It is clear that in SLE these mechanisms are impaired. Even SLE patients with 
inactive SLE demonstrate an inability to remove B cells expressing self-reactive BCRs [124]. 
Later in development, failure to select against entry of autoreactive B cells into the mature 
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repertoire is a hallmark of lupus [125]. It is unclear what leads to failure of these main central 
tolerance checkpoints. Evidence supports roles for both BCR and TLR signalling in 
maintaining central tolerance and limiting activation of anergic B cells. Genetic disruption in 
important BCR signalling genes such PTPN22 and LYN lead to expansion of auto-reactive B 
cell clones [83] and genome-wide association studies (GWAS) have implicated several B-
cell specific genes immediately after BCR signalling such as BANK1 and BLK with SLE 
[126]. All types of TLR except TLR3 use IRAK4 and MyD88 to signal and patients deficient in 
IRAK4 and MyD88 all have elevated frequencies of poly-reactive new emigrant/transitional B 
cells which indicate a break in central B cell tolerance [127]. Indeed, it is postulated that B 
cells with both BCRs recognising nucleic acid auto-antigens and nucleic antigen recognition 
by TLRs may be selected against, and any mechanism breaking this co-recognition may 
lead to increased generation of autoreactive B cells [83]. Furthermore, it has been 
demonstrated that not just abnormalities within the pathways themselves, but uncoupling of 
TLR and BCR-ERK signalling permits autoimmunity [128] and it is likely that either 
abnormalities within these signalling pathways, or abnormalities in their interactions, permit 
breaks in tolerance. 
 
Several mechanisms of peripheral tolerance for B cells also exist. Immature CD10+ 
transitional B cells expressing IgM/IgD emigrate from bone marrow to peripheral blood 
wherein they mature into naïve B cells [129]. After encountering antigen and T-cell help 
within follicles of secondary lymphoid organs, mature naïve B cells migrate to germinal 
centres (GC) to undergo clonal expansion, somatic hypermutation and Ig heavy-chain class-
switch recombination. During the GC reaction, naïve antigen specific B cells mature into 
either memory B cells or Ig-secreting plasma cells [129], although the affinity maturation is 
stochastic in nature and susceptible to generation of auto-antigen specific antibodies. 
Recent work would suggest that the rates of SMH are lower in antibodies from SLE patients 
[130]. Co-stimulation from CD4+ T cells has been implicated in maintaining peripheral 
tolerance. Indeed, the GC reaction itself is implicated as a tolerance checkpoint [52]. This 
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concept may be best exemplified with the 9G4 idiotype antibody, encoded by VH4-34 heavy-
chain gene rearrangements that bind B220 self-antigen, and are commonly found in 
autoantibodies [131]. This idiotype is normally negatively selected in GCs: healthy 
individuals do not contain 9G4+ memory B cells despite being present in the mature 
recirculating repertoire. In SLE individuals, 9G4+ cells can circumvent negative selection in 
GCs and expand into a memory B-cell and plasma population, and 9G4-expressing B-cells 
as well as 9G4-containing anti-dsDNA antibodies correlate with disease activity [132]. 
Further, backwards mutation to germ line antibody results in loss of DNA binding activity 
[133]. Indeed, the VH4-34 heavy-chain itself is intrinsically autoreactive and antibodies 
encoded from this heavy-chain will react against carbohydrates located on red blood cells 
[134]. Interestingly B cells with VH4-34 based BCRs largely do not pass through the GC 
[135] and are heavily selected against and therefore do not appear to undergo SHM [130]. 
 
Abnormalities in central and peripheral tolerance can lead to loss of anergy and auto-
reactivity, often associated with reproducible B cell phenotypes. Some of the  described 
abnormalities of SLE include increases in memory B cells, particularly “atypical memory B 
cells” - CD27- IgD- memory B cells [136-138] together with a decrease in IgM+ non-switched 
memory B cells [139]; IgD-only memory B cells; Cd11b+ B1 cells [140]; T1 B cells [141]; 
CD19hi CD21lo [139] and plasmablast populations [132,136,142].  
 
Within the memory compartment several subsets have been shown to be abnormally 
expanded. An expanded population of transitional B cells and switched CD27+ B cells as 
well as a distinct population of CD27-IgD- B cells with a memory phenotype in normal 
circumstances [129]. This is supported by molecular data that peripheral B-cell repertoire in 
SLE can be shaped by somatic hypermutation, whereas the Ig repertoire initially generated 
by V(D)J recombination appears similar to normal controls[143]. Furthermore, the frequency 
of memory B cells is increased in the peripheral blood of SLE patients undergoing 
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immunosuppressive therapy, potentially reflecting a pool of treatment-resistant B cells that 
will serve as a reservoir for future flares [142]. 
 
Plasmablasts have also been implicated in SLE pathogenesis. Short-lived 
plasmablasts (CD27high/HLA-DRhigh) appear capable of producing anti-DNA antibodies and 
their frequency in blood correlates with disease activity whereas long-lived plasma cells 
(CD27high/HLA-DRlow) produce stable autoantibody titres to extractable nuclear antigens such 
as –Sm, -Ro, or –La [144]. HLA-DRhigh plasmablasts are likely freshly generated 
plasmablasts and most strongly correlate with disease activity. Several lines of evidence 
suggest that plasmablasts are derived from GC reactions: they are reduced after inhibiting 
GC reactions [145] and circulating plasma cells in patients with active SLE expressed highly 
mutated IgVH genes with mutations consistent with GC hypermutation [142]. 
 
Additional mechanisms that may contribute to breaching peripheral B cell tolerance 
may be dysregulated Fc gamma receptor signals. Fc gamma receptors form a family of 
receptors that recognise immune complexes for the purposes of either suppressing or 
enhancing immune responses [146]. Four different classes of Fc receptors have been 
identified: Frei (CD64), FcɣRII (CD32), FcɣRIII (CD16), and FcɣRIV [147]. Functionally there 
are two different classes of Fc, activating and inhibitory receptors which transmit their signals 
via immunoreceptor tyrosine-based activation (ITAMs) or immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) and balance of these two forms of Fc allows balanced immune 
responses [147]. The inhibitory FcɣRIIb is expressed on all cells of the immune system – 
prominently in B cells which do not express any other Fc gamma receptors - with the 
exception of T cells and natural killers and is part of the family of immune inhibitory 
receptors. It was hypothesised to play a role in regulating BCR signalling, the strength of 
which will determine whether a B cell will undergo proliferation and differentiation into an 
antibody-secreting plasma cell, or to induce apoptosis in inappropriately activated B cells. 
Indeed, FcɣRIIb-/- mice spontaneously develop a lupus-like disease characterized by the 
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production of autoantibodies and severe glomerulonephritis [148]. Polymorphisms within 
human FcɣRIIb have been strongly linked to SLE [148]. Notably, the Fcgr2b-/- mouse did not 
develop problems with early events, such as in receptor editing in bone marrow or the 
development of IgM+ autoreactive B cells. After class switching to IgG, however, FcɣRIIb 
was essential to prevention of expansion of autoreactive B cells and their maturation into 
plasma cells [148], highlighting a late stage role in prevention of the initiation of severe auto-
reactivity. 
 
These combined data allow several theories for the role of B cells in SLE. First, that 
abnormalities in central B cell tolerance checkpoints allow emergence of autoreactive clones 
due to defective negative selection [149]. Second, that defects that allow differentiation of 
anergic B cells through TLR and/or BCR signals may lead to T-independent forms of the 
disease. Also, indirect evidence of therapeutic disruption of GC reactions and GC patterns of 
antibody mutation suggest that SLE may result from dysregulated GC activity and potentially 
preferential selection by autoantigen [149]. Further to this, it has been suggested that this 
increased GC activity may result from ectopic generation of GCs [150] or possibly SHM 
developing autoreactive clones [151]. 
 
1.3.3 T cells in SLE 
 
Although classically considered a B cell mediated disease, emerging lines of 
evidence implicate T cells in SLE pathogenesis. Numerous mouse models have described 
the need of T cells or T cell-derived molecules for SLE development, regardless whether 
diseases is thought to originate from follicular or extrafollicular B cells. For example, 
depletion of CD4+ T cells in NZB/BXSB F1 mice ameliorated disease [152]. MRL.lpr mice 
made deficient in CD40L, which abolishes T cell help for B cells, did not develop anti-dsDNA 
antibodies not kidney damage [153]. Deletion of SAP, which is expressed by T cells and NK 
cells and is required for optimal TCR signalling and Tfh formation, prevents lupus in a 
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number of mouse models; MRL.lpr [154], sanroque [48] and pristane-induced lupus [155]. T 
cell-derived products have also been shown to be instrumental for SLE pathogenesis. For 
example, IFN- is the key driver of lupus in sanroque mice [156] and is also required for 
lupus nephritis in NZB/W F1 mice [157] and MRL.lpr mice [158]. Another T cell derived 
cytokine, IL-21, has been shown to be required for SLE development in BXD2 [159] and 
BXSB-Yaa mice [160]. Tregs – defined in mice as CD4+ Foxp3+ T cells - have also been 
shown to be reduced in mouse models of lupus including NZB/W F1 [161] in which 
exogenous Treg transfer reduced disease progression and mortality [162] and the 
production of autoantibodies [163]. The latter was proposed to occur through a role of Tregs 
in inducing B cell anergy. Treg transfer from young (disease-free) lupus-prone NZM2328 
mice also prevented anti-dsDNA antibodies but not kidney disease in thymectomised 
recipient mice from the same strain [164]. It has also been suggested that in some lupus-
prone mice such as MRL.lpr that despite Tregs being functional, effector T cells may be less 
sensitive to suppression [165]. In the case of sanroque mice, Tregs also appear to be 
functional [166], but T effectors may be resistant to suppression due to excessive IFN- 
production [156]. 
 
Despite this evidence for a role of T cells in lupus development in mice, there are 
also lupus-prone mouse models such as BAFFR transgenic mice in which lupus can develop 
in the complete absence of T cells [119], again suggesting SLE is heterogeneous with T-
dependent and T-independent pathways of B cell dysregulation. 
 
A number of T cell abnormalities have been reported in human SLE. Although for 
most it is not possible to conclude whether they are a cause or consequence of the disease, 
they provide evidence of dysregulation and support the notion they may contribute to some 
aspects of pathology. Some of the T cell phenotypes found in human SLE are summarised 
here.  
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Lipid rafts are micro-domains that form on the membrane of T and B cells. In T cells, 
these rafts bear TCR-CD3 complexes and associated signalling molecules. In normal T 
cells, TCR stimulation leads to clustering of these rafts to aid formation of the immunological 
synapse, allowing for cognate interactions with corresponding molecules on APCs [167]. 
SLE T cells, however, display pre-clustered lipid rafts indicating T cells are primed for 
activation. Further, the composition of these rafts is abnormal, with greater expression of 
FcRγ, Syk, and phospholipase C γ (PLCγ), with reduced expression of the lymphocyte 
kinase Lck [167]. Although cytotoxic T lymphocyte antigen 4 (CTLA4), a co-stimulatory 
molecule that is an important negative regulator of TCR signalling, is generally found to have 
increased expression in SLE T cells it is unable to suppress aberrant T cell activation [168]. 
A trial of atorvastatin, an inhibitor of 3-hydroxy-3methylgluteryl CoA reductase that disrupts 
lipid rafts, reduced co-localisation of CD45 and Lck with reduction in IL6 and IL10 production 
[169]. Abnormalities in the TCR-CD3 complex have been identified wherein the CD3ζ chain 
is decreased and, structurally and functionally, replaced by an FcRγ chain which binds the 
spleen tyrosine kinase (Syk) instead of ZAP70 which is conventionally bound by the CD3ζ 
chain. This results in exponentially increased signalling with a markedly increased calcium 
flux [170]. 
 
Activated T cells express CD40 ligand (CD40L) and provide cognate help to CD40-
expressing B cells via the CD40-CD40L interaction. T cells from SLE patients have 
increased baseline CD40L and increased and prolonged expression of CD40L upon 
activation [171,172]. Reciprocally, hyperactive B cells can stimulate T cells to upregulate 
CD40L which can, via positive feedback, provide help to autoreactive B cells resulting in 
autoantibody production. A possible suggestion for the observation of elevated CD40L 
relates to the increased nuclear factor of activated T cells, NFAT, found in SLE T cells. 
NFAT itself targets the CD40L promoter to drive expression, and its elevation is likely related 
to the enhanced calcium flux that occurs in SLE T cells (as discussed earlier) [173]. 
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Regulatory T cells (Tregs) are a subset of CD4+ T cells that constitute approximately 
1-2% of human PBMCs [174]. Human Tregs are characterised by expression of CD25, and 
high expression of FOXP3, a transcription factor essential to the development and function 
of Tregs [175]. Indeed, after the discovery of the important role for Tregs in maintaining 
tolerance and the role of FOXP3 in their development, point mutations in FOXP3 were 
identified as the genetic basis of the disease called immune dysregulation, 
polyendocrinopathy, enteropathy X-linked syndrome (IPEX) [176]. CD25, a component of the 
IL-2 receptor, is highly expressed on Tregs, yet may also be found on recently activated 
CD4+ T cells [177]. Apart from naturally occurring thymically derived Tregs, stimulation of 
peripheral CD4+ T cells with anti-CD3 and anti-CD28 can induce Foxp3 expression [178] 
and therefore Tregs have been classified as inducible (iTregs) or natural (nTregs) thymically 
derived Tregs and it is thought that expression of Helios may distinguish these subtypes in 
the periphery [179]. In 2006, low expression of the alpha chain of the IL-7 receptor (CD127) 
was found to be a consistent feature of bona fide human Tregs [177,180], and is now used 
routinely for Treg identification in human studies.   
 
Several studies have been conducted addressing the role of Tregs in human SLE 
with conflicting results. Until CD127 was described to better identify human Tregs [180], it is 
likely that using CD25 and/or FOXP3 was not identifying bona fide Tregs due to the 
limitations discussed previously. Whether measuring those CD4+ expressing either CD25+ 
or CD25high, thought to have greater repressive ability, both subsets have been reported to 
be reduced in SLE [181-183] although this has been disputed [184,185]. It has been 
reported that SLE patients with active disease have reduced numbers of CD4+CD25high cells 
compared with SLE patients with inactive disease [182]. FOXP3 expression is equally 
confounding, with reports that CD4+CD25+FOXP3+ Tregs are reduced in SLE patients 
compared with healthy individuals [186-188] and other studies reporting they are equivalent 
[184,185]. It is also possible that it is either Treg function that, as seen in some mouse 
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models, is impaired, or the sensitivity of effector T cells or APC’s to Treg suppression that is 
altered. 
 
1.3.4 Cytokine signalling in SLE 
 
Several cytokines have been reproducibly associated with SLE. The classic 
association is with type 1 interferon, but other significantly associated cytokines are IL-1, IL-
2, IL-6, IL-10, IL-21 and IFN-y.  
 
Interferons are cytokines produced in response to foreign pathogen which function to 
enhance immune responses. Based on the receptor they signal through, there are three 
major types of IFN; type 1, type 2, and type 3 interferon. Type 1 interferons include IFN-, 
IFN-, IFN-, IFN-, and IFN- which are capable of binding IFNAR [189]. In humans IFN- 
is the sole known type II interferon [190]. Type 3 interferons include IFN-l, although this has 
only recently been proposed as separate class of IFN [190]. Of these, IFN- is considered 
the key IFN in lupus pathogenesis [191]. It is often elevated in the serum of SLE patients and 
its long-term administration in other diseases (i.e. viral hepatitis) is associated with the 
development of SLE-like symptoms[191]. Peripheral leukocytes from SLE patients largely 
overexpress a large number of IFN-stimulated genes [192]. Whilst IFN- may be produced 
by numerous leukocytes, plasmacytoid dendritic cells (pDCs) have the capacity to rapidly 
produce large quantities of IFN- [193]. One of the most potent inductors of this IFN- 
response in pDC is TLR7/9 and TLR 9 stimulation by RNA and DNA, respectively [193]. 
pDCs are derived from circulating monocytes, often in response to IFN-, and indeed wild 
type monocytes cultured in the serum from SLE patients may rapidly differentiate into pDCs 
[191]. It is therefore apparent that excess IFN- in SLE patients may reflect a positive 
feedback loop wherein increased IFN- initiated by TLR activation leads to pDC 
differentiation and therefore more IFN- production [191]. Beyond the effects on pDC 
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differentiation, type 1 IFNs can affect adaptive immune responses. In human B cells, pDC-
derived IFN- generates non-Ig-secreting plasmablasts in conjunction with IL-6 [194]. In T 
cells, type 1 IFN prevent activated T-cell death during inflammatory responses, particularly 
CD8+ effector T lymphocytes. The result of this is further release of nucleosome SLE 
autoantigens, therein sustaining the type 1 IFN cycle [195]. 
 
IL-1 has potent anti-inflammatory properties, IL-1 is an important mediator of tissue 
damage in chronic autoimmune diseases. IL-1 receptor antagonist (IL-1R) blocks IL-1 in a 
dose dependent manner, and its production is regulated at least partially through FcγR 
dependent pathways. Monocyte-derived IL-1β production was found to be reduced, 
regardless of disease activity, and in active disease monocytes had deficient FcγR -
mediated production of IL-1R [196] but increased amounts of IL-1Ra in response to 
adherent IgG [197]. High levels of IL-1R were observed during disease flares not involving 
the kidney whereas low levels characterised renal flares [198]. Similarly implicated is IL-2, a 
T cell and B cell growth factor. Absence of IL-2 in Il2-/- mice results in lymphoid hyperplasia 
and inflammatory bowel disease. SLE T cells have been found to produce decreased 
amounts of IL-2 following antigenic stimulation which is more pronounced in patients with 
active disease [199] although other cohorts do not report a difference in baseline or induced 
IL-2 [200]. Its receptor, sIL-2R is released by activated lymphocytes and has generally, but 
not universally, been found to be elevated in patients with active SLE [201-203]. Elevation in 
sIL-2R seems to predict and correlate with disease flares, particularly those with nephritis 
[204,205]. 
 
IL-6 has been strongly implicated in B cell hyperactivity and immunopathology in 
human SLE. Lymphoblastic lines from SLE patients produce increased levels of IL-6 and 
inhibition of IL-6 reduced anti-dsDNA production by lymphoblastoid cells in vitro [206]. Basal 
and stimulated IL-6 messenger RNA (mRNA) levels in PBMCs are reproducibly increased in 
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SLE patients and correlate with disease activity [207,208]. Furthermore, SLE patients have 
elevated serum levels of IL-6 although the correlation between disease activity and IL-6 is 
imperfect[209-212]; a contrarian study reported few SLE patients having elevated serum IL-6 
[213]. In aggregate, IL-6 tends to be elevated in PBMCs and immortalised B cell lines from 
patients with SLE although higher levels do not necessarily correlate with disease activity. 
 
IL-10 is a pleiotropic cytokine with both potent anti-inflammatory effects but also the 
capacity to induce B stimulation and autoantibody production. IL-10 is elevated in both 
human and murine SLE and may be either contribute to disease, or increase in an attempt to 
regulate Th1 immune responses. Knockout of IL-10 in MRL/Faslpr mice results in more 
severe lupus and higher mortality [214] although conversely therapeutic anti-iL-10 antibodies 
significantly improve survival in NZB/W mouse models [215]. In SLE patients both baseline 
and stimulation-induced IL-10 production are elevated, but do not correlate with disease 
activity [207,211,216]. 
 
IL-21 is increasingly implicated in the development of SLE. IL-21 was initially 
reported to be produced by activated CD4+ T cells [217], with both Th2 [218], Th17 [219-
221] and Tfh [222] cells implicated as the source of Il-21. In mice, it is involved in late B cell 
development inducing mature B cells to differentiate into Ig-secreting PCs. IL-21 receptor 
deficiency in mice results in impaired IgG responses [223] but essentially normal B cell 
populations, whereas in humans IL-21 is the major cytokine that induces B-cell activation, 
PC differentiation and immunoglobulin production [224,225]. With anti-CD40, IL-21 is 
capable of inducing PC differentiation whist inhibiting anti-IgM and IL-4 induced proliferation 
[217]. These diverse effects are likely mediated through sustained expression of Bcl-6 and 
Blimp-1 in GC B cells [226]. Given its important role in mediating plasma cell physiology and 
influencing the GC reaction it is unsurprising that IL-21 is increasingly implicated in SLE. In 
patients with SLE higher IL-21 and IL-21 mRNA levels are observed [227,228] and case-
control analysis suggests that mutation in the IL-21 gene is a risk factor for SLE [227]. In the 
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SLE mouse model BXSB-Yaa mouse have elevated serum and transcriptional IL-21 [229] 
and genetic ablation of IL-21R in these mice led to SLE-like disease [160]. 
 
IL-12, IL-18 and interferon-γ have been associated with SLE. Elevated serum levels 
of IL-12, IL-18 and IFN-γ have been observed in small cohorts of patients with active SLE 
[230,231], although again levels do not appear to associate with disease activity. However, 
significant data exists that IL-12 production is not elevated in SLE [232]. Further, interferon 
gamma production itself was not found to be elevated in SLE at basal or stimulated levels 
[200] and in a further study was reportedly found at reduced levels [216].  
 
1.3.5. Deoxyribonucleic Acid and Ribonucleic Acid in SLE 
 
Lupus is characterised by production of autoantibodies directed against nuclear 
antigens, particularly DNA [1].  It is therefore unsurprising that DNA, and the antibodies 
against DNA, have been shown in several different ways to be important in disease 
pathogenesis. These autoantibodies are thought to contribute directly to the pathogenesis of 
SLE as they precede the development of clinical disease in most, but not all, patients and 
levels of anti-DNA antibodies correlate with disease activity [233,234]. The development of 
an immune reaction to endogenous DNA is thought to result in disease by permitting 
deposition of antigen-antibody complexes in tissue, and therefore leading to local activation 
of complement and recruitment of inflammatory lymphocytes. The strongest evidence of the 
pathogenic nature of DNA is observed in SLE pedigrees involving genes implicated in both 
local and systemic DNA and/or RNA degradation. Polymorphisms in DNA processing genes 
such as TREX1 [235], DNASE1 [236] and RNASEH2 [237] family members are recognised 
causes of monogenic lupus and overlapping diseases such as Aicardi-Goutiere syndrome. 
These defects in DNA processing are thought to contribute to SLE pathogenesis as 
excessive DNA and or RNA overwhelms tolerance mechanisms in the immune system. CpG 
motifs in DNA derived from either bacteria or self can activate TLR9 [238,239], and RNA 
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activates TLR7, possibly in association with autoreactive BCR [240]. Evidence of an 
important role of TLR7 in lupus comes from the finding that lupus in BXSB-Yaa mice is 
caused by a TLR7 duplication [241,242]. 
 
1.3.6 Human Leukocyte Antigen (HLA) in SLE 
 
Major histocompatibility complex (MHC), termed human leukocyte antigen (HLA) in 
humans, is located in the short arm of chromosome 6. The strong association of HLA with 
multiple autoimmune diseases has been largely elicited from genome-wide association 
studies (GWAS). Indeed, in meta-analyses of these genes HLA is reproducibly the most 
potent genetic risk factor when studying genetic risk with GWAS [243]. HLAs may be divided 
into three classes. Class I HLAs are responsible for presentation of peptide from inside the 
cell, such as viral fragments, and induce CD8+ cytotoxic immune responses. Class II HLAs 
are responsible for presenting peptide from outside cell to CD4+ T –lymphocytes for the 
purposes of eliciting helper T responses and subsequent B-cell antibody responses. Class III 
HLAs region encodes classical complement components, C2, C4A, and C4B [244]. The 
most consistent HLA associations with SLE are in the class II alleles HLA-DR3 (DRB1*0301) 
and HLA-DR2 (DRB1*1501) in predominantly white populations [245]. Inherited deficiencies 
of C4A and C4B, part of the class III HLA region, are strongly associated with SLE [246,247] 
which is unsurprising as monogenic forms of SLE exist relating to C4 mutations [248]. 
Ultimately, due to limitations in GWAS, disease associations are limited to regions 
encompassing HLA class II and II, and more specifically DR3- and DR2-bearing ancestral 
haplotypes [244]. HLA subsets may also influence disease manifestations, such as 
development of specific antinuclear autoantibodies Ro/SSA found in 25-50% of SLE cases, 
which associate with the HLA-DR2/DR3 and HLA DQw1/DQw2. 
 
Several non-mutually exclusive mechanisms have been proposed to explain the 
reproducible association of DR/DQ with autoimmunity. First, that variation in binding regions 
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of associated DR/DQ molecules could lead to preferential presentation of limited, specific 
sets of self-peptide, allowing autoreactive T cells to escape tolerance and enter the 
periphery [249]. The increasing evidence of the post-translational modifications of known 
autoantigens  - i.e. citrullination, deamidation in RA and celiac disease respectively -, make 
this a very attractive mechanism to explain how T cells tolerised against self-antigens, can 
be activated by modified self-peptides that are now seen as foreign. Second, that DR/DQ 
could select autoreactive T cells or fail to select appropriate Treg populations [250]. Thirdly, 
that preferential binding in DR/DQ heterozygous subjects could occur through epitope 
stealing by one MHC over another which could affect whether an immune response is 
mounted [251]. Finally, it is postulated that misfolded class II MHC may inappropriately 
present endogenous antigen [252]. Ultimately several mechanisms are likely to contribute 
yet it is unclear exactly the quanta that each contributes to overall predisposition. 
 
1.3.7 Conclusion 
 
Diverse mechanisms are implicated in the pathogenesis and pathophysiology of SLE. 
These mechanisms may be universally linked, perhaps as a result of confirmation bias, to 
the development of B cell auto-reactivity. Complement may exert its effect through several 
mechanisms; complement deficiency may result in failure to clear apoptotic or nuclear debris 
leading to excess auto-antigenic stimulation of B cells; or failure to repress or regulate 
complement activation, particularly of the classical pathway, may precipitate tissue damage 
and subsequent auto-inflammation. Defects within B cells themselves are also strongly 
implicated through several possible mechanisms including BCR or TLR signalling defects 
that permit breaks in central or peripheral tolerance, or B cell predisposition to recognition of 
auto-antigen or differentiation into plasmablasts. Within T cell lineages, excessive T cell help 
or abnormalities in enforcing tolerance within or outside germinal centres have been 
implicated, as the possibility of impaired Treg-mediated suppression. Further, increased 
antigen production through either complement or failure to appropriately clear or process 
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DNA may result in excessive auto-antigen presentation to B cells. Excess auto-antigen 
presentation may also be a feature of B cells themselves, or resulting from excessive type 1 
interferon driving APC differentiation and therefore B and T cell activation, or even failure of 
clearance of nucleic debris.  Finally auto-antigens may be aberrantly selected for 
presentation, post-translationally modified so as not to be recognised as self any longer, or 
aberrantly presented by particular or misfolded MHCs, resulting in selection of auto-reactive 
B cells. 
 
1.4 The genome and genetic mutations 
 
The basic structure and function of the human genome in biology is well established, 
based on sequences of deoxyribonucleic acid (DNA) purines, guanine (G) and cytosine (C), 
or pyrimidines, adenine (A) or thymine (T), which are bound to a backbone comprised of 
alternating phosphate and sugar residues. The pyrimidine uracil (U) may replace thymine in 
ribonucleic acid (RNA). These strands are then paired through complementary base pairing 
where adenines will only bind to thymine and guanine will only bind to cytosine through 
hydrogen bonds. This complementation permits all genetic information to be held on each 
strand. Together, these bases constitute the genome, and the human genome is composed 
of over three billion bases of DNA encoding 19,000 genes [253]. 
.  
The genome may be divided into introns and exons, or non-protein coding and 
protein coding segments, respectively. Only 1.5% of the human genome consists of protein-
coding exons, however, with the majority as intronic or non-protein coding sequence 
[254].This non-protein coding sequence is constantly changing, a process permitting 
evolution and adaptation to the environment [255]. Furthermore, it contains significant and 
yet poorly understood regulatory regions, that consist not only in gene promoter an 
enhancing regions, but also encodes for both small and long non-coding RNAs that control 
multiple aspects of gene expression and function[256].  
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The chemical structure of DNA biases the patterns of mutation.  Transitions, where 
the class of nucleotide is preserved (such as purine to purine mutation) are more common 
than purine to pyrimidine (or vice versa) transversions. Once occurred, any mutation will 
then either increase or decrease in frequency through positive selection or negative 
selection. Mutation that confers a selective advantage may become enriched due to positive 
selection – an example being the low frequency of lactose intolerance in European 
populations due to expansion of a lactase variant that was positively selected in the dairy-
heavy diet of this group [257]. The benefit in nutrition promoted survival of this genetic 
variation. Conversely, genetic variants that impair fitness of the organism by >1% will be 
under negative selection and be observed at uncommon frequencies. Over multiple 
generations and depending on potency, these variants will ultimately disappear [258]. The 
majority of variants, however, only modestly alter gene function in either a positive or 
negative polarity, if at all. These variants experience neutral selection, not being selected for 
or against as they do not alter the individual’s fitness. Furthermore, patterns of mutation may 
also bias according to gene function, an example being the immune system where functional 
diversity may translate into a significant host advantage upon immune challenge [259]. 
 
Genetic variation exists on a spectrum of size; from cytogenetically apparent 
segments [260] to individual single nucleotide variants (SNVs). Advances in sequencing 
technology and mathematical modelling have permitted increasing detection of intermediate 
sized genetic variation in the form of copy number variation (CNV), defined as any insertion 
or deletion of genomic material greater than 1000 base pairs. It is estimated that there are 
over 10 million common (minor allele frequency >1%) [261] SNVs in the genome, although 
only a small subset are likely to result in phenotypic differences between populations. 
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1.4.1 Single nucleotide variation 
 
SNV are single base-pair changes in DNA sequence that can occur within introns, 
exons, and regulatory elements. Once considered “junk DNA”, it is increasingly apparent that 
intronic sequences have numerous critical functions including splicing, gene activation, or 
generation of regulatory non-coding RNAs. Variants within introns can therefore have 
significant consequence due to changes to gene splicing, resulting in loss of segments of 
translated protein, or due to changes to gene activators or repressors resulting in altered 
gene expression. Furthermore, many observations regarding non-coding genome remain 
unexplained such as the presence of ‘gene deserts’ which are regions up to 3 Mb that are 
devoid of genes and the loss of which has no obvious effect [262], the impact of high 
alternative splicing rates (35-60%) for coded genes [263], or even the exact role of ultra-
conserved elements which are extraordinarily highly conserved regions between 
evolutionarily distant species [264]. The basic overview of the genome described above 
does not encompass the growing complexity and importance that is recognised for intronic 
sequences. 
 
SNV in exons, the portion of the genome coding for amino acids, can have profound 
effect on protein structure and function. Exonic SNV fall into two broad classes; synonymous 
variants wherein the SNV does not change the encoded amino acid and which therefore 
have no functional consequence, and non-synonymous variants which change the encoded 
amino acid and can potentially alter protein function [258]. The potential impact, and basis of 
that impact, for each amino acid change is large. These range from loss of residues with 
critical functions (such as tyrosines or serines) to changes to secondary structure of the 
protein from alterations in electropotential charge. SNVs typically have two alleles, meaning 
within a population there are two commonly occurring base-pair possibilities at a particular 
genetic position. The frequency of the SNV is given in terms of minor allele frequency (MAF), 
or the frequency of the less common allele. A MAF of 0.4 estimates that 40% of the 
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population carries one base type, whereas 60% of the population carries the other base type 
(the major allele). 
 
Although this most likely reflects historical biases towards studying coding regions of 
the genome, it is estimated that non-synonymous variation accounts for approximately half 
of the known genetic lesions responsible for human inherited disease [265]. However, recent 
advances in CNV detection has also increased the recognition of the contribution of CNV to 
human disease [266]. 
 
1.4.2 Copy number variation 
 
Current estimates suggest around 12% of the genome is subject to copy number 
variation [267]. CNV, large gains or loss of >1000bp of DNA, can arise both meiotically and 
somatically, as evidenced by the finding that identical twins can have different CNVs [268]  
and that repeated sequencing in different organs and tissues from the same individual can 
vary in copy number [269]. Indeed, CNV seems to be as important as SNV in determining 
differences between individuals and is a major driving force for evolution[270]. As mentioned 
previously, in the case of CNV there exists a bias for mutation; CNVs are enriched in genes 
involved in olfaction, immunity and secreted proteins [271]. It is uncertain whether this due to 
greater adaptation in these genes (genes relevant to interaction with the environment) or 
whether CNV is better tolerated in these genes, and therefore they are purged at a lower 
rate than in other areas of the genome. The major issue confronting current research is the 
unavailability of adequate tools that can accurately detect CNV. Microarrays and chromatin 
precipitation arrays are used predominantly, although advances in bioinformatics analysis 
mean that smaller CNVs are now detected by WES or WGS. Larger CNVs, due to alignment 
of small read fragments in WES/WGS, are more difficult to detect. However, improving 
recognition of CNV as a form of genetic variation has resulted in discoveries of susceptibility 
Chapter 1: Introduction 
 
39 
 
to complex genetics diseases such as psoriasis [272], Crohn’s disease [273] and 
glomerulonephritis [274]. 
 
1.4.3 Chromosomal variation 
 
With the 1956 discovery of correct chromosome numbers in humans, rapid flow of 
discoveries in the era of clinical cytogenetics followed. Classic and relatively common 
examples include chromosomal variation in chromosome 21 (trisomy 21, Down Syndrome) 
and chromosomal variation in the X chromosome (Loss of X, 45 X, Turner syndrome or gain 
of X, 47 XXY, Klinefelter syndrome) [275]. As a class, chromosomal disorders are often 
highly penetrant and typically associated with first-trimester abortions. Those foetuses that 
survive through to birth often exhibit a spectrum of disease including developmental delay 
and multiple organ pathology. In relation to autoimmunity, chromosomal variation is of 
interest given the association of Yaa mice with the development of systemic autoimmunity. 
Yaa mice have duplication the TLR7 encoding portion of the X chromosome to their Y 
chromosome, and therefore male mice have increased expression of TLR7 which is 
sufficient to induce systemic autoimmune disease [276]. Indeed, although numbers are low 
an association between additional X chromosomes (Klinefelter’s syndrome) and SLE has 
been reported [277]. 
 
1.5 Studying mutation in human disease 
 
1.5.1 Genome wide association study, whole exome sequencing and whole 
genome sequencing 
 
With the exception of limited case studies and focused sequencing methodologies 
such as linkage study and candidate gene sequencing, two large-scale methods of analysing 
complex genetic disease have been used. Genome-wide association studies (GWAS) use 
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capture chips or beads conjugated with small DNA sequences. Alleles are then detected by 
differential hybridisation with the sample DNA. This technology permitted rapid and 
simultaneous detection of over a million SNVs and resulted in advances in our 
understanding of genetically complex disease. However, although a major advance it also 
had significant limitations. Firstly, given the large number of variants being analysed and the 
requirement for these SNVs to be sampled in large SLE cohorts, the risk of false positive 
associations is high [278]. That is, when a large number of variants is tested in a large 
cohort, the likelihood that any detected difference is due to random chance rises. To account 
for this, various rigorous statistical tests such as Bonferroni and Sidak tests are need to 
correct for multiple sampling, and probability cut-offs for significance are restrictive (in the 
order of x10-8). The statistical rigour needed to be confident of genetic association with 
disease therefore limits the type of SNVs that can be used as probes. As a consequence, 
rare variants will occur at too low rates to adequately power an association, and therefore 
only common alleles can be used as detectors. There has been, however, significant 
success in identifying single gene disorders using linkage and GWAS [279,280]. GWAS 
studies have uncovered multiple genetic loci that illuminate disease-causing pathways in 
polygenic conditions, although a large fraction of genetic heritability remains unaccounted for 
in most complex diseases. This has raised the possibility that the genetic architecture of 
complex disease may consist on a spectrum of common and rare variants. In the case of 
complex autoimmunity there is much debate as to what fraction of genetic risk do GWAS 
alleles contribute to [281], with a large recent studies suggesting that rare variants will not 
explain the missing heritability [282]. 
 
Whole exome sequencing (WES) and whole genome sequencing (WGS) are 
relatively recent advances in sequencing that have allowed greater resolution and 
examination of individual genomes. The process is based on fragmentation of DNA with 
redundant sequencing of millions of DNA fragments in lengths of 25 – 1000 bases. These 
reads are then assembled into large contiguous segments that can be ordered and oriented 
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against a reference genome to construct the individual genome. The process of alignment is 
computation-intensive but allows resolution of novel and rare mutations [283]. Whole exome 
has been, until recently, the mainly used platform primarily due to cost. However, the cost of 
sequencing whole genomes has declined significantly and, with modest improvements in 
exon coverage, is likely to become the gold standard of massively parallel sequencing. The 
greatest value of either WGS or WES is their capacity to identify both rare and novel SNV. 
Unfortunately, in comparison with issues of adequate detection faced by GWAS, WES and 
WGS face the inverse problem, generating vast amount of genomic data; how to predict or 
rank those SNVs poses a significant challenge. 
 
1.5.2 Computational prediction of the effects of a mutation 
 
Several methods and computational programs have been created in an effort to 
predict whether SNVs may affect protein function. These predictive programs compute at 
genomic or protein levels, typically relying on conservation or chemical change to predict the 
effect of variation. Commonly employed programs are Sorting Intolerant from Tolerant 
(SIFT), Polymorphism Phenotyping2 (Polyphen2; PPN), and the Combined Annotation 
Dependent Depletion (CADD) tool. 
 
To predict the effect a mutation may have on protein function, the SIFT program was 
developed to prioritise substitutions for further study [284]. It relies heavily on conservation of 
amino acids. If a specific residue is always conserved, any change is considered deleterious. 
If a specific type of amino acid residue is conserved at the site (i.e. hydrophobic amino 
acids), any class of that amino acid will be tolerated and any change of type (i.e. from 
hydrophobic to charged) will be predicted to be deleterious.  
 
Polyphen2 differs from SIFT by imputing additional information besides charge 
conservation [285]. The sequence containing the SNV is compared against a database of 
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domains and functions. If the amino acid is annotated as a binding site or another important 
functional residue it is scored. Also, important residues beyond the substituted amino acid in 
the sequence are recorded and if a 3D structure is known, PPN checks whether the mutated 
residue is in proximity to the important residues in that structure. Therefore, for sequences in 
relatively unknown regions, there will be minimal differences in predictive ability between 
PPN and SIFT. 
 
The most recent iteration of bioinformatics prediction of damage is CADD, designed 
to overcome several limitations to bioinformatics prediction such as circularity (discussed 
below). CADD integrates diverse genomic predictions to contrast scores on fixed alleles 
(alleles with no variation) in humans with simulated de novo variants [286]. 
 
Although the above tools can be useful for enhancing discovery of pathogenic 
variants, a number of significant limitations exist. First, predictions vary widely with input and 
output; conservation predictions are genome-wide but do not use functional information and 
are not allele-specific. Protein-based predictions (i.e. SIFT, Polyphen) only deal with coding 
variants and therefore do not consider the majority (>99%) of genetic variation. Both SIFT 
and PPN programs are significantly better at predicting loss-of-function than gain-of-function 
and derived most of their predictive ability from conservation [287]. Each predictive tool has 
its own scoring system and it is difficult to compare or reconcile these scores. Most 
significantly, these programs are trained on known pathogenic mutations and are subject to 
major ascertainment biases. This concept, referred to as circularity, describes how these 
programs are used to evaluate variants or proteins that were themselves used to train the 
programs’ predictive models [288]. The natural consequence of this is that the 
generalisability is poor. 
 
These combined limitations, therefore, impair the predictive ability of SIFT, PolyPhen 
and CADD. SIFT and PPN have poor sensitivity (69% and 68%, respectively) as well as 
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poor specificity (13% and 16%, respectively) [287]. In a recent study, CADD, which was 
thought to bring significant improvements, did not score better [289]. It is therefore 
recommended that all three prediction tools are used to limit the risk of missing potentially-
damaging variants.  
 
1.6 Genetic theory for SLE 
 
Twin studies report disease concordance of 24-75% and 2-5% for identical and non-
identical twins, respectively [290,291], indicating a significant genetic contribution towards 
SLE. Epigenetic modifications account for part of the disease discordance in monozygotic 
twins[292]. Despite the well-recognized familial clustering of SLE [293,294], only rarely do 
single nucleotide variants (SNVs) associate with SLE in a Mendelian pattern [295] with most 
genetic predisposition following complex patterns of inheritance [294]. Genome-wide 
association studies (GWAS) have identified numerous loci which confer modest risk for SLE 
[296-298] and whose molecular and physiological consequences are uncertain [299,300]. 
 
The cumulative consequences of genetic variants identified by GWAS might account 
for sporadic cases of lupus, although available data leave a substantial component of the 
estimated genetic risk unaccounted for by common variants. Furthermore, common variants 
are unlikely to account for familial clustering of lupus as this would require consistent co-
segregation of an improbably large number of weak-acting variants. An alternative theory is 
that a small number of variants with highly deleterious effects act in concert to cause SLE. 
These variants would be expected to be rare and therefore may have evaded analysis in 
GWAS, although it is possible that rare variants are in linkage disequilibrium with common 
GWAS-identified variants. Rare variants are now identifiable by whole-exome sequencing 
(WES) or whole-genome sequencing (WGS). Although studies in other non-immune 
complex diseases such as autism [301] and epilepsy [302] have suggested a significant 
proportion may be caused by novel or rare variants, whether this mechanism applies to 
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lupus remains unknown [282,300]. The rare variant hypothesis is supported by results from 
ethyl-nitrosurea mutagenesis programs, which have identified single point mutations that 
result in SLE-like phenotypes in mice [166] and spontaneous lupus-prone models in which 
single point mutations in genes such as Fas [303] also cause disease. Since single gene 
mutations can cause human SLE [304] as mentioned in 1.3.1, it is plausible that the disease 
could arise from oligogenic defects. Furthermore, as mentioned previously, larger structural 
variation such as CNV has been show to predispose to SLE [274] nephritis and 
autoimmunity. Regardless of the possible contribution of rare variants, the discovery of 
multiple common variants associated with SLE through GWAS has provided significant 
advances in our understanding of the genetic susceptibility to SLE. 
 
1.6.1 Genes implicated in SLE 
The evident familial association with SLE has resulted in lengthy investigation into 
possible causative gene variants. Over several decades increasingly sophisticated 
technology has permitted increasingly broad and unbiased methods of identifying risk 
variants. 4 major groups were initially, and now reproducibly, associated with SLE. The first 
gene associations with SLE were with the major histocompatibility complex (MHC), which 
encode the human leukocyte antigen (HLA)[305]. Indeed, class II alleles HLA-DR2 
(DRB1*1501) and HLADR3 (DRB1*301) are reproducibly associated with SLE and the HLA-
DQ and HLA-DR alleles have strong associations with SLE autoantibodies[306]. Second, 
rare variants manifesting in Mendelian patterns led to the discovery of the importance of 
complement. As noted in 1.3.1, C1q and C1r/C1s deficiency were found to have 
exceptionally high risks for SLE[62] and C4 and C2d deficiency were also substantially 
associated with risks for SLE[62]. A further striking observation is that SLE associated with 
these complement deficiencies has earlier onset,  typically more severe disease, as well as 
afflicting males equally to females[62]. Third, the Fc gamma Fcγ receptor family were 
strongly and reproducibly associated with SLE. FCγRI (CD64), FCγRII (CD32), and FCγRIII 
(CD16) are particularly implicated[307], and perhaps unsurprisingly as these genes function 
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to bind and clear IgG antibodies and IgG-containing immune complexes from the circulation. 
The pathophysiolgocial importance of circulating antibody-antigen complexes to end organ 
damage is further highlighted by the association of FCγRIIa and FCγRIIIa in particular with 
lupus nephritis[308]. The last major group of initial genes discovered associated with SLE 
were those associated with type 1 interferon. As noted in 1.3.4, type 1 interferon activity is 
strongly linked to the pathogenesis SLE, and early targeted associations of interferon genes 
identified interferon regulatory factor 5 (IRF5) and tyrosine kinase 2 (TYK2) genes with risk 
alleles for SLE[309]. Subsequently, both original and subsequent IRF5 mutations have been 
confirmed to increase risk and indeed, several IRF5 mutations in combination are capable 
for additively increasing this risk of SLE[310].   
 More recently, GWAS have permitted unbiased ascertainment of alleles associated 
with SLE. It is apparent, as stated earlier, that these alleles may be grouped under several 
broad categories of complement activation, interferon signalling, antigen presentation, and B 
cell signalling. A summary of these genes has been listed in Table 3. 
 
Table 3. List of known genetic variants associated with SLE 
Gene Location Odds Ratio Variation Discovery 
HLA-DR2, 
HLA-DR3 
6p21.32 2.4 Haplotype 1971 
C2 6p21.32 5.0 Deletion 1972 
C4 6p21.32 4.3 CNV 1974 
C1q 1p36.12 10 Deletion 1981 
FCGR2A 1q23.3 1.6 H131R 1996 
FCGR3A 1q23.3 1.4 F176V 1997 
FCGR2B 1q23.3 1.7 I232T 2002 
PDCD1 2q37.3 1.2 PD1.3G/A 2002 
PTPN22 1p13.2 1.4 R620W 2004 
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IRF5 7q32.1 1.6 SNP 2005 
FCGR3B 1q23.3 1.2 CNV 2005 
STAT4 2q32.2 2.2 SNPs 2006 
IRAK1 Xq28 1.5 SNPs 2007 
TREX1 3p21.31 25 SNPs 2007 
MECP2 Xq28 1.3 SNPs 2007 
TNFSF4 1q25.1 1.4 SNPs 200/8 
CRP 1q32.2 1.3 -707 SNP 2008 
ATG5 6q21 1.2 SNPs 2008 
PTTG1 5q33.3 1.2 SNPs 2008 
UBE2L3 22q11.21 1.2 SNPs 2008 
PXK 3q14.3 1.2 SNPs 2008 
PHRF1 11p15.5 1.2 SNPs 2008 
ICA1 7p21.3 12. SNPs 2008 
NMNAT2 1q25.3 1.1 SNPs 2008 
ITGAM 16p11.2 1.6 R77H 2008 
TNFAIP3 6q23.3 2.0 SNPs 20008 
BLK 8p23.1 1.3 SNP 2008 
BANK1 4q24 1.2 R61H 2008 
TNIP1 2q35 1.3 SNP 2008 
Adapted from Ramos, P et. Al 2010 
 
Not only have specific gene loci been reproducibly associated, but these loci also 
offer an insight into the complex pathogenesis of SLE itself. Broadly, it is apparent these 
genes may be clustered into cellular defects or signalling pathways as discussed in 1.2 
pathogenesis of SLE. Gene loci with the highest risk (by odds ratio) for SLE are classical 
complement components C1q [311], C4A [312], C4B [313], and C2 [70], followed by type 1 
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interferon genes IRF5, ITGAM[297,298], and B cell signalling genes BANK1 [296] and BLK 
[298].  
Within the cluster of B cell signalling genes, two major patterns are observed. First, 
BANK1 and BLK are essential to BCR signalling. BLK is a src-kinase family member which 
is activated upon BCR engagement. The primary known consequence of BLK activation is 
phosphorylation of BANK1 with subsequent activation of Phospholipase C Gamma 2 
(PLCG2) and intracellular calcium flux. Therefore, these two genes would appear to be 
directly related to BCR-mediated signalling. The other two risk genes which are prominent in 
B cell biology are IL10 and PR domain zinc finger protein 1 (PRDM1) which encodes the 
master transcriptional regulator BLIMP1. As noted in 1.3.4, IL-10 is important in the 
development of antibody-secreting plasma cells and antibody production. BLIMP1 is 
essential to the transformation of activated B cells into antibody-secreting plasma cells. This 
would suggest that genetic lesions affecting BCR signalling and plasma cell differentiation 
are critical to development of SLE. 
 
1.7 Hypothesis and aims of this thesis 
 
As reviewed in this chapter, SLE is a genetically complex condition in which 
disturbances in virtually all limbs of the immune system have been implicated. These 
disturbances cluster at a genetic and physiological level around disturbances in regulation of 
B cell tolerance, or abnormalities in auto-antigen handling or presentation. Using genetic 
leads established by GWAS, and the easing of technical and financial limitations to 
identifying and proving the effect of rare SNV, we now have the capacity to investigate the 
role of genetic variation in SLE. This thesis hypothesises that rare or novel SNV and CNV 
are capable of contributing substantially to SLE pathogenesis. 
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2.1 Human patients and DNA sequencing 
  
Written informed consent was obtained as part of the Australian Point Mutation in 
Systemic Lupus Erythematosus study (APOSLE). This research cohort recruits patients with 
SLE and their families residing within Australia. The diagnosis of SLE is made by the treating 
physician and does not require the ACR criteria definition. The study was approved by the 
Australian National University and ACT Health Human Ethics Committees. From the cohort, 
patients were prioritised for WES based on early age of onset, severity of disease, or familial 
clustering. Saliva was collected in Oragene™ DNA self-collection kits and purified using 
PrepIT™ DNA purification kits (Oragene) and treated with RNAse out (Ribonuclease A, 
Qiagen Cat# 19101). DNA samples were enriched with Human SureSelect XT2 All Exon V4 
Kit and sequenced by Illumina HiSeq 2000 (Illumina, Inc.). Bioinformatics analysis was 
performed at JCSMR, ANU by the team of Dan Andrews, Matt Field and Vicki Cho. Raw 
sequence reads were aligned to the reference genome (Hg19) and single nucleotide variants 
and small insertions and deletions called using SAMTools. All SNVs of interest were 
confirmed by PCR and Sanger sequencing.  Amplifluor to detect BANK1W40C in the APOSLE 
cohort was performed using the CHEMICON Amplifluor SNPs HT Genotyping System Fam-
Joe kit S7909 (Merck-Millipore). 
 
2.2 Expression vectors and mutagenesis 
 
The following expression vectors were obtained: untagged Blk (OriGene 
Technologies), SAMSN1-MycDDK (OriGene Technologies), myc-Lyn (GeneCopoeia, Inc), 
Traf3-FLAG (GeneCopoeia, Inc). IRAK2-FLAG was a gift from Rob Brink and BANK1-V5 
was a gift from C. Castillejo-López (Uppsala University). Site-directed mutagenesis was 
performed using the Quikchange I and II Site directed mutagenesis protocols (Agilent 
Technologies).  
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2.3 Antibodies 
 
Antibodies for western blotting, immunofluorescence imaging and co-
immunoprecipitation studies were as follows: mouse anti-human Blk (SC-65980; Santa 
Cruz), Rabbit anti Blk (K-23; Santa Cruz); Mouse anti V5 (clone SV5-Pk1, MCA1360, AbD 
Serotec); mouse anti FLAG M2 (F1804; Sigma); mouse anti-myc (9E10; Merck Millipore); 
rabbit anti-TRAF3 (c-20). (Santa Cruz), mouse anti-CD71 (DF 1513, Sigma); mouse anti 
phosphotyrosine-HRP (R&D Systems). Secondary antibodies were conjugated to HRP 
(Jackson ImmunoResearch),  Alexa 568 or Alexa 488 (Molecular Probes, Invitrogen). 
 
2.4 Transfection, immunoprecipitation and Western blotting 
 
HEK 293T cells were transfected (Lipofectamine 2000; Life Technologies) with the 
relevant plasmids as per manufacturer’s recommendation. Cells were lyzed using NP-40 
lysis buffer and immunoprecipitated with the relevant antibody using Protein G Sepharose 
(GE Healthcare) and the relevant antibody. For co-immunoprecipitation experiments 
transferrin receptor was used as isotype control. Immunoprecipitants were resuspended in 
SDS-buffer and boiled prior to electrophoresis on 8% SDS-PAGE gels. Gels were 
transferred to nitrocellulose membranes (BioRad Laboratories), blocked overnight (TBST + 
skim milk powder; or 5% BSA for phosphotyrosine blots) and probed with the relevant 
primary and secondary antibodies. Membranes were developed with enhanced 
chemiluminescence developer (Western Lightning Plus ECL; Perkin Elmer). TLR-9-
expressing HEK293 cells (InvivoGen) were transfected as above with the relevant plasmids 
and mCherry reporter plasmid using Lipofectamine 2000 (Life Technologies). TLR9-
HEK239s were cultured for 24 hours before being sorted by mCherry expression using a 
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FACS Aria II, and 2.5 x105 mCherry positive TLR9-HEK293s were plated and stimulated 
with 5µg/ml CpG (ODN 2006, InvivoGen). 
 
2.5 Analysis of cytokine secretion 
 
Supernatants from human cell lines and mouse B cells were analysed by BD™ 
Cytometric Bead Arrays (CBA) using the Human Inflammatory Cytokine kit (BD Biosciences) 
and the Mouse Inflammation kit respectively, as per manufacturer’s recommendation at time 
points indicated. 
 
2.6 Dual luciferase assays (DLAs) 
 
HEK293T cells were transfected with a firefly luciferase reporter (100ng; Stratagene), 
pRL-Tk (10 ng; Promega), Renilla luciferase control reporter, pC1-EGFP (100 ng; Clontech) 
and IRAK2 Strep-HA plasmids (as indicated). 48h later DLAs were performed as per 
published protocols [314,315]. 
 
2.7 Isolation of PBMCs and generation and activation of human LCLs 
 
Patient PBMCs were isolated using Ficoll Paque density gradient (GE Life 
technologies) and cryopreserved at 2x106/ml using complete RPMI + 10% DMSO. PBMCs 
were transformed into lymphoblastoid cell lines (LCLs) through transfection with Epstein-Barr 
Virus with addition of Cyclosporine A. LCLs were stimulated with 1:1000 R848 (InvivoGen), 
5µg/ml CpG (ODN7909 from Invivogen), 1µg/ml E. Coli lipopolysaccharide (Sigma-Aldrich), 
or 20µg/ml anti-IgA+IgM+IgG F(ab’)2 (Jackson Immunoresearch). 
 
2.8 LUminescence-based Mammalian IntERactome (LUMIER) 
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LUMIER was done by Alex Weber and Hui Wei as described for a recent 
Myddosome study [314]. In brief, 10000 HEK cells/well in triplicate 96-wells were transfected 
with 20 ng Protein A and Renilla fusion plasmids each (Lipofectamine 2000; Invitrogen). 48 h 
post-transfection cells were lyzed, raw Renilla activity measured and Protein A-tagged 
proteins (and Renilla-tagged interactors) purified using magnetic, IgG-coated beads. Bound 
Renilla luciferase activity was measured and an interaction signal was processed by dividing 
the activity of bound Renilla luciferase to the amount of raw Renilla activity for each 
transfection, and then normalized to the specific signal for a Protein A-only (no bait) 
condition. 
 
2.9 Transcriptome profiling of human PBMCs by microarray 
 
Transcriptome profiling was performed by Virginia Pascual’s team (Baylor institute 
Texas and analysed by Romaine Bancherau from her team. In brief, amplified RNA from 
BANK1W40C/+ PBMC and healthy controls was hybridized to Illumina HT-12 V4 beadchips 
(47,231 probes) and scanned on an Illumina Beadstation 500. Illumina’s GenomeStudio 
version 2011.1 with the Gene Expression Module v1.9.0 (Illumina, San Diego, CA) was used 
to generate signal-intensity values. After background subtraction, the average normalization 
recommended by GenomeStudio was used to rescale the difference in overall intensity to 
the median average intensity for all samples across multiple arrays and chips. In addition, 
conventional adult SLE PBMC samples were obtained from the public domain (GEO, 
GSE24706) for comparison. Each dataset was normalized to the median of its own group of 
healthy controls. IFN modules were obtained from a previously defined blood module 
framework [316]. Differentially expressed transcripts between conventional adult SLE PBMC 
and BANK1+/W40C PBMC were identified by Welch’s t test, with Benjamini-Hochberg FDR < 
0.05. 
 
2.10 CRISPR-Cas9 genome editing of human B cell lines 
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CRISPR/Cas9 editing of the Ramos B cell line was performed with help from Dr Vicki 
Athanasopoulos. Dr Athanasopoulos performed cloning of guide RNA and transfection of 
Ramos cells and I performed cell sorting and sequencing of sorted cells. The vector 
px330[317] (Addgene), which expresses Cas9 and the sgRNA, was linearized with BbsI and 
gel-purified. A pair of complementary 18mer oligomers targeting a single site within the 
SAMSN1 genome (primer sequences available upon request) was annealed and ligated to 
the linearized vector. pX330 expressing the sgRNA of interest was transfected along with an 
mCherry plasmid into the Burkitt’s lymphoma cell line Ramos using the NEON transfection 
system (ThermoFisher Scientific) according to the manufacturer’s instructions. mCherry+ 
single cells were sorted 24-48hrs later into 96-well plates and individual clones expanded 
until confluent.  gDNA was extracted by digesting cells with proteinase K (0.1% Tween20,  
100M EDTA, 500ug/mL Proteinase K, 1x HF Phusion buffer) at 56OC for 40 mins, followed 
by incubation at 95OC for 8 mins. A region of approximately 300 base pair flanking the 
variant was PCR amplified (primer sequences available on request) using Phusion DNA 
Polymerase II (ThermoFisher Scientific) and presence of the mutation confirmed by Sanger 
sequencing. All sequencing was carried out at the ACRF Biomolecular Resource Facility and 
Genome Discovery Unit, Australian National University. 
 
2.11 CRISPR-Cas9 mediated genome-editing of mouse zygotes 
 
C57BL/6 mice were housed under specific pathogen-free conditions. All mouse 
procedures have been approved by the Australian National University Animal 
Experimentation Ethics Committee. (AEEC A2014/058 and A2014/016) under the NHMRC 
Australian code of practice. gRNA from Samsn1 and Bank1 were synthetically generated 
and obtained from Sigma while Blk gRNA and Cas9 protein were obtained from PNABio. 
Oligomers and ssOligomers were purchased from IDT. C57BL/6Ncrl female mice (4-5 weeks 
old) were super ovulated with Pregnant Mare Serum Gonadotrophin (PMSG) 5UI day 1 and 
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Human Chorionic Gonadotrophin hormone (HCG) 5UI day 3. After detection of a vaginal 
plug of the super ovulated females, mouse zygotes were harvested from the ampullae and 
were placed in KSOM medium (Sigma). Cas9n protein (100 ng/µl) was co-injected with a 
mixture of sgRNA (50 ng/µl each) and ssOligomer (100 ng/µl) into the cytoplasm of the 
fertilized eggs into M2 medium (Sigma). After micro-injection, the zygotes were incubated 
overnight at 37ºC and 5% CO2 and 2 cell-stage embryos were surgically transferred into the 
uterus of pseudopregnant CD1 recipient females at 2.5 dpc. Three weeks after birth mouse 
ears were punched. DNA was extracted and Sanger sequencing performed to confirm the 
mutations. Selection and testing of gRNAs, mouse zygote preparations and micro-injections 
were carried out at the Australian Phenomics Facility, Australian National University by a 
team from the Ausralian Phenomics facility initially led by Stuart Read and more recently by 
Dr Gaetan Burgio; microinjections were performed by Nikki Ross. The sequencing was 
carried out at the ACRF Biomolecular Resource Facility and Genome Discovery Unit, 
Australian National University. 
 
2.12 Antinuclear antibodies and kidney immunofluorescence 
 
Four month-old mice were sacrificed and serum and kidneys were harvested. Dilute 
plasma (dilution 1:40) was incubated on Hep-2 substrate. Bound antibody was detected with 
anti-mouse IgG conjugated with fluorescein isothiocyanate (FITC). Immunoglobulin and C3 
deposition analysis was performed on cryopreserved kidney sections. 7 μm acetone fixed 
sections were blocked with 3% bovine serum albumin and stained with anti-IgG Alexa Fluor 
488 (Invitrogen), anti-IgA FITC (Southern Biotech), anti-IgM FITC (BD Pharmingen) and anti-
C3 FITC (MP Biomedicals). Fluorescence intensity was evaluated with an Olympus XI 71 
microscope. 
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 2.13 Electron microscopy 
 
Samples from Kidney were fixed in 2% Glutaraldehyde (overnight) in Sorenson’s 
phosphate buffer (0.1M) then postfixed with 2% osmium tetroxide (Electron Microscopy 
Sciences, Hatfield, PA, USA) in 0.1 M sodium phosphate buffer for 2 hours. En bloc staining 
with 2% uranyl acetate preceded dehydration through a graded series of ethanols. 
Specimens were infiltrated with low-viscosity epoxy resin (Spurr’s replacement; TAAB 
Laboratory and Microscopy, Berkshire, UK) using a mix of 50:50 ethanol to TAAB resin for 2 
hours followed by TAAB resin for 3 hours, embedded, and set overnight at 70 degrees C. 
Ultrathin (80 nm) sections were cut from several blocks (3) per sample. Sections were 
mounted on 150-mesh copper/palladium grids, stained with Reynold’s lead citrate, and 
viewed on a transmission electron microscope (JEOL 1011; JEOL Ltd, Tokyo, Japan). 
Images were captured using a digital camera (MegaView G2; Olympus, M¨unster, Germany) 
and software (iTEM; Olympus). Stains and electron microscopy were performed by Mark 
Koina at the Canberra Hospital.  
 
2.14 Single cell suspension and flow cytometry 
 
Single-cell suspensions were prepared from spleens of indicated mice. Suspensions 
were prepared in RPMI 1640 media (Gibco) by mechanical disruption and gentle pipetting 
through 70 mm nylon mesh filters (BD Biosciences). To stain for surface markers, cells were 
incubated with each antibody layer for 30 min in the dark at 4 C and washed thoroughly with 
ice-cold FACS buffer (2% FCS and 0.1% NaN3 in PBS) between each layer. Intracellular 
staining was performed using the Intracellular Staining Kit (eBioscience) according to the 
manufacturer’s instructions. 
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3.1 Development of a scoring system for WES variants 
 
We first sequenced the exomes of several individuals with childhood onset disease 
or members of multiplex families. As with complement deficiencies we expected that familial 
segregation and early onset/male onset may represent more potent genetic lesions. WES 
data were assembled against a reference genome using the Raijin supercomputer at the 
National Computation Infrastructure, Australian National University (ANU) [235]. 
Bioinformaticians (D Andrews and M Field) at the JCSMR then aggregate data from several 
public databases to create a report on the identified SNVs, including frequency, in silico 
predictions, gene expression, human disease association and murine association. The 
approach adopted in this thesis to handling the WES variants was to attempt to filter SNVs 
that were highly unlikely to associate with disease and therefore enrich for disease causing 
variants. As the central hypothesis of this thesis is exploration of rare variants, scores were 
attributed to minor allelic frequency. Initial algorithms also include weighting to Polyphen2 
score, and gene expression. All variants were then ranked and variants in the top three 
ranks (scoring >4 out of 7) were reviewed. 
 
The strategy for proof of causation for these variants was established. First, that 
variant inheritance would suggest epistatic interaction to explain familial clustering of 
autoimmunity. Secondly, that we test the ability of the SNV to alter protein function. Thirdly, 
that we may test the consequence of this altered protein function in changing physiology. 
Finally, that we may test how the alterations in protein function and cell physiology alter 
complex system biology, ultimately leading to autoimmunity. 
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3.2 Rare variants in BANK1, BLK, IRAK2 and SAMSN1 identified in SLE patients 
 
In the exome from the first proband sequenced (proband A – A.II.2 in Fig.4a), two 
variants attained the highest score (score 7, Fig. 2), a rare (minor allele frequency (MAF) = 
0.004) heterozygous missense mutation in BANK1 (4:102751014, G/C, rs35978636) 
encoding a tryptophan to cysteine substitution at amino acid position 40 predicted to be 
damaging (Polyphen2 (PPN) =0.98) and a rare (MAF= 0.006) heterozygous missense 
mutation in IRAK2 (3:10177883, C/A, PPN:0.98, rs11465864) encoding a serine to tyrosine 
change at amino acid position 47. In addition to their high score, both genes were implicated 
in SLE pathogenesis. First, BANK1 was reproducibly associated with SLE and complex 
autoimmunity through GWAS as mentioned previously. Although IRAK2 has not directly 
been implicated, family member and signal complex partner IRAK1 has been previously 
implicated in SLE[318]. Further analysis identified a second mutation in IRAK2, IRAK2T508M 
(3:10238797, C/T, MAF=0.001, PPN:0.65, rs144752184, IRAK2T508M) on the maternal allele, 
indicating IRAK S47Y/IRAK2T508M compound heterozygosity in proband A. 
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Figure 2. Numbers of non-synonymous SNV by score. Scoring is awarded for allele 
frequency, bioinformatic prediction of damage, association with immune function and 
immunological disease. A high score indicates the strongest correlation. Scoring of variants 
in proband A identifies BANK1W40C and IRAK2S47Y as top scoring SNV. 
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An Amplifluor™ was performed on the APOSLE cohorts by the Australian Phenomics 
Facility, ANU, to test two concepts. First, if GWAS-identified alleles may be not be the risk 
alleles, but rather associate with disease through sharing of a common haplotype with a 
deleterious variant. Second, if BANK1W40C is significantly associated with autoimmunity then 
it should be significantly enriched in an autoimmune population. Indeed, we identified the 
BANK1W40C allele in nine of 150 SLE patients (6%) and three individuals from 222 unaffected 
controls (1.3%), odds ratio (OR) of 4.66 (95% CI: 1.1 - 27.1, p=0.017). In comparison, the 
common GWAS BANK1 risk haplotype identified by rs10516487 (R61H, MAF 0.25, OR=1.4 
(95% CI: 1.3-1.5, p=3.74 x10-10)[296] and which encompasses W40 (Fig. 3) is predicted to 
be benign (PPN=0). To replicate these findings the AmplifluorTM was repeated in a second, 
albeit smaller, SLE cohort (n=99) and BANK1W40C was observed at a lesser frequency in two 
of 99 patients (2%). A possible explanation is racial differences in the cohorts as BANK1W40C 
has not been reported in Asian populations and the second cohort was comprised of 47% 
individuals of Asian background, whereas only 24% of individuals from the original cohort 
were of Asian descent. The rarity of the allele and smaller cohort may have resulted in 
insufficient power to detect the variant. A lack of clinical data in the second cohort precluded 
a detailed examination of phenotypic differences. 
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Figure 3. Schematic of protein structure of BANK1 and juxtaposition of BANK1W40C and the 
common SLE risk BANK1R61H variants in areas of linkage disequilibrium 
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To investigate the possibility of oligogenic lupus, as possibly observed with proband 
A, we sought epistatic interactions with the BANK1W40C variant in the other SLE patients 
carrying BANK1W40C. We proceeded to perform WES on all nine SLE probands carrying the 
BANK1W40C SNV. In all 9 individuals, we identified rare or novel heterozygous SNVs in genes 
encoding proteins known to interact directly with BANK1 or in BANK1-regulated signalling 
pathways – BCR, TLR, and CD40 – amongst the highest scoring SNVs. Kindred DNA was 
available to construct a pedigree for 3 of the 9 SLE probands (Fig. 4). The clinical phenotype 
of all probands are listed in table X. The segregation of the different variants with disease 
suggested predisposition to SLE was determined by co-inheritance of BANK1W40C with a 
second rare SNV in genes involved in B cell activation. 
 
In Proband A, as stated, we identified BANK1W40C and both IRAK2S47Y and 
IRAK2T508M. Proband B had inherited BANK1W40C and a heterozygous BLKR131W variant 
(8:11550181 C/T, MAF:0.009, PPN:1, rs73663163) from each parent. Proband C carried the 
BANK1W40C allele and a heterozygous SAMSN1T198A variant (21:14500705 T/C, MAF:0.01, 
PPN:0.98, rs62227165) (Fig. 5 and Fig. 6). Each variant encoded amino acid changes within 
important domains of the translated protein (Fig. 7) and all were predicted to be damaging by 
Polyphen2 (Fig. 7). This implicates BANK1W40C in SLE pathogenesis and suggests that a 
second pathogenic SNV in a gene associated with BANK1 function is required for induction 
of SLE in this subset of patients. 
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Table 3. Clinical phenotype of probands and SLE patients with BANK1W40C variant 
Gender Birth 
year 
Ethnicity Renal MSK-skin Oral Vessels Thrombosis Serositis Serology Complement 
Proband A 
 
Female 1999 Caucasian No Tenosynovitis 
Photosensitive 
rash 
Ulcers Raynauds No No ANA: 1:1280 
Speckled 
DsDNA negative 
 
Low C4 
Proband B 
 
Female 1971 Caucasian No Arthritis 
Photosensitive 
rash 
Sicca Raynauds No No ANA> 1:1280 
Speckled 
Lymphopaenia 
DsDNA negative 
SS-A positive 
SS-B negative 
HGG 
 
Normal 
Proband C 
 
Female 1974 Caucasian Class 
III LN 
Photosensitive 
rash 
Sicca Raynauds No No ANA>1:1280 
Homogeneous 
DsDNA (>500iu/L) 
SS-A positive 
SS-B negative 
Anticardiolipin + 
 
Low C3 
Low C4 
APOP30 
 
Female 1988 Caucasian No Arthritis 
Photosensitive 
rash 
No Raynauds No No ANA 1:1280 
Speckled 
DsDNA negative 
HGG 
 
Low C3 
Low C4 
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Gender Birth 
year 
 
Ethnicity Renal MSK-skin Oral Vessels Thrombosis Serositis Serology Complement 
APOP37 
 
Male 1923 Caucasian No Arthritis Ulcers Raynauds DVT Pleural ANA 1:1280 
Homogeneous 
Lymphopaenia 
DsDNA (<100iu/L) 
Anticardiolipin + 
 
Low C4 
APOP49 
 
Female 1961 Caucasian No Arthritis 
Photosensitive 
rash 
No Raynauds No No ANA >1:1280 
Homogeneous 
Lymphopaenia 
DsDNA (<500iu/L) 
Anti-RNP 
HGG 
 
Low C3 
Low C4 
APOP69 
 
Female 1957 Caucasian No Alopecia Ulcers 
Sicca 
No DVT No ANA + 
DsDNA negative 
Anticardiolipin + 
 
Normal 
APOP85 
 
Female 1974 Caucasian No Arthritis 
Rash 
Sicca Raynauds 
Seizures 
No No ANA >1:1280 
Homogeneous 
DsDNA positive 
SS-A positive 
SS-B positive 
 
 
Low C3 
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Gender Birth 
year 
 
Ethnicity Renal MSK-skin Oral Vessels Thrombosis Serositis Serology Complement 
APOP89 
 
Female 1939 Caucasian CKD Rash Sicca No DVT No ANA >1:1280 
Homogeneous 
DsDNA (<100iu/L) 
Anticardiolipin + 
SS-A positive 
SS-B negative 
Low C3 
Low C4 
ANA=Antinuclear antibodies; DsDNA=double stranded DNA antibodies; DVT= deep vein thrombosis; CKD=chronic kidney disease; 
HGG=Hyperga
Chapter 3: SNV in BANK1 and interacting partners predisposes to SLE  
66 
 
mmaglobulinaemia.
 
 
Figure 4. Pedigrees of SLE probands and segregation with BANK1 and associated 
genotypes. (ANA = antinuclear antibody, SS = Sjogren’s Syndrome, SLE = Systemic Lupus 
Erythematosus, APS = Antiphospholipid Syndrome, RA = Rheumatoid Arthritis) 
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Figure 5. Pedigrees of SLE probands and segregation with BANK1 and second variants 
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Figure 6. Chromatograms of heterozygous SNVs BANK1W40C, IRAK2S47Y, IRAK2T508M, 
BLKR131W, and SAMSN1T19A. 
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Figure 7. Schematics of protein structures and relevant domains and position of residue 
changes as a result of identified variants 
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3.3 Rare gene variants alter protein function 
 
3.3.1 IRAK2S47Y and IRAK2T508M are gain of function mutations and IRAK2 interacts 
with BANK1  
 
In addition to BANK1W40C, proband A had compound heterozygous novel mutations in 
IRAK2. IRAK2 is an important component of the TLR-MyD88 signalling complex. In 
response to TLR ligation, IRAK2 forms homo- and hetero-dimers with family members 
IRAK4 and IRAK1. MyD88 complex formation via TLR ligation results in IRAK family 
member phosphorylation, with subsequent recruitment of TRAF6 and NF-κB activation [319]. 
The S47 residue lies in the death domain of IRAK2, which directly interacts with the death 
domains of other IRAK family members and of MyD88 (PDB 3MOP) (Fig. 8). Modelling of 
the structure formed by these complexes was performed by J. Babon at the Walter and Eliza 
Hall Institute of Medical Research, Melbourne University, which identified Serine 47 (Fig. 8) 
located at the interfaces between the four monomers of the IRAK2 and IRAK4 molecules. In 
every case there was a cavity between the sub-units immediately adjacent to S47 that could 
accommodate the larger tyrosine side chain in the IRAK2S47Y mutation  with little, if any, re-
orientation. Given the more bulky nature of the tyrosine side-chain and the fact that it 
contains a potential hydrogen bond donor moiety at its distal end, we predicted this mutation 
may stabilise the overall complex. To test this hypothesis, we used SDM and generated 
plasmids expressing the IRAK2S47Y and IRAK2T508M variants. Both variants were tested using 
LUMIER interactions performed in the lab of A. Weber, University of Tuebingen, Germany, 
and displayed increased binding affinity for wild type IRAK2, IRAK4 and TRAF6 suggesting 
increased recruitment to the MyD88 signalling complex (Fig. 9). Our collaborators at the 
Weber lab then tested whether the enhanced interaction resulted in a change in TRAF6-
mediated NF-κB activation and observed that both IRAK2 variants increased NF-κB 
transcriptional activity, an effect increased by the combination of these variants (Fig. 10). 
BANK1 has also been implicated in negative regulation of TLR7/8 and TLR9 signalling and 
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postulated to interact with MyD88 through its putative TIR domain [320]. We therefore 
hypothesized that BANK1 and IRAK2 may coexist as part of the MyD88 complex. To test 
this, BANK1 and IRAK2 were expressed in HEK293T cell lines and co-immunoprecipitation 
analyses demonstrated a novel physical interaction between the two proteins (Fig. 11), 
which was not perturbed by the BANK1W40C variant. In summary, BANK1 forms a complex 
with IRAK2, and proband A is heterozygous for two gain of function mutations in IRAK2 
which increase interaction with other IRAK family members and TRAF6 resulting in 
increased NF-κB signalling. 
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Figure 8. Structure of death domains of IRAK2 (red) in complex with IRAK4 (blue) (PDB 
3MOP). The death domains of the two proteins form a left-handed helical super-assembly 
with the death domains of MyD88 (not shown). Four copies of both IRAK2 and IRAK4 are 
present (labelled A-D above). In three of the four monomers, Serine 47 (white) is visible in 
this orientation and is located at an IRAK2:IRAK2 interface whilst in the fourth it is located at 
the IRAK4:IRAK2 interface (not shown). Note the cavity between the sub-units immediately 
adjacent to each S47, indicating the importance of the serine at position 47 as a site for 
docking within the TLR signalasome Modelling by J. Babon. 
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Figure 9. LUminescence-based Mammalian IntERactome (LUMIER) quantifying the 
interaction between IRAK2 signalling partners (IRAK4, IRAK2 and TRAF6) with IRAK2S47Y 
and IRAK2T508M. Luciferase intensity indicates strength of interaction between proteins on the 
x-axis and the variants in IRAK2 as indicated. Each condition is the median of 3 replicates. ** 
= p<0.01, **=p<0.001, ****=p<0.0001. LUMIER performed by A. Weber. 
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Figure 10. Dual Luciferase reporter assays to quantify NF-κB activation in response to 
IRAK2 variants. Bars represent median of triplicates for each condition. Representative of 3 
repeat experiments (p=0.002) ELISA by A. Weber. 
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Figure 11. Co-immunoprecipitation of BANK1 and IRAK2  HEK293T lysates 48 hours after 
co-transfection, blotted with antibodies against IRAK2 and BANK1 demonstrate a two-way 
interaction between the proteins. Representative of at least 3 separate experiments 
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3.3.2 BLKR131W is kinase inactive 
 
We next set out to test whether the identified variants altered protein function. 
BANK1 was initially identified as a substrate of Lyn [321] and is known to interact with the 
Src-family member BLK after BCR crosslinking [322]. In proband B, in addition to the BANK1 
variant we identified a rare heterozygous mutation in BLK (BLKR131W rs144615291). As with 
BANK1, a common BLK variant, rs13277113, has been shown to segregate with SLE by 
GWAS [298,323]. CD79a and CD79b, which form part of the BCR complex, phosphorylate 
BLK C-terminal tyrosine residues after BCR crosslinking [324] altering the secondary 
structure to expose the catalytic domain responsible for the phosphorylation of BANK1 [299]. 
Therefore, BANK1 is directly linked to BCR signalling through interaction with BLK and Lyn. 
BLK kinase activity depends on interactions between SH2 domain arginine residues and C-
terminal phospho-tyrosines [325]. Arginine 131 is located on Helix αA (αA2), as modelled by 
J Babon, and is known to co-ordinate phosphorylated tyrosine residues in a number of SH2 
domain:ligand structures alongside the conserved arginine at αB5 (Fig. 12). This co-
ordination will be disrupted in the presence of the R131W change. To test whether BLKR131W 
alters the conformation and kinase activity of BLK, we used site-directed mutagenesis (SDM) 
to generate cDNAs encoding the BLKR131W variant as well as a constitutively-active BLKY501F 
variant [326]. When expressed in HEK293T cells, BLKR131W was unable to adopt the high 
molecular weight kinase active form observed consistently with the BLKY501F variant and also 
present in WT BLK (Fig. 13), suggesting that BLKR131W is kinase inactive.  
 
As BANK1 is a known substrate of BLK and BLK is known to require activation 
through the BCR to phosphorylate BANK1, we predicted BLKR131W would impair 
phosphorylation of BANK1. When co-expressed in HEK293T cells we confirmed that 
BLKR131W had significantly impaired ability to phosphorylate BANK1 compared with wild-type 
BLK or BLKY501F (Fig. 14). In summary, BLKR131W is unable to acquire an open active form 
and is therefore unable to phosphorylate BANK1. 
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Figure 12. Predicted BLK Arginine 131 (shown in white stick representation) is located on 
Helix αA (αA2) and is known to co-ordinate phosphorylated tyrosine residues in a number of 
SH2 domain:ligand structures alongside the conserved arginine at αB5 (R151 in BLK, red 
stick representation). Modelling by J. Babon. 
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Figure 13. α-phosphotyrosine blotting of expressed BLKWT, BLKY501F and BLKR131W 48 hours 
after transfection with 2ug of indicated DNA. Arrows indicate a high and low molecular bands 
correlating with phosphorylation fo BLK. The lower molecular weight band corresponds to 
the inactive form (closed configuration due to lack of phosphorylation). Representative of 3 
repeat experiments 
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Figure 14.  α-phosphotyrosine blotting of precipitated BANK1 72hours after co-transfection 
with BLK of indicated genotypes. Immunoblotting of pTyr demonstrates impaired 
phosphorylation of BANK1 by BLKR131W, but appropriately increased phosphorylation by 
BLKY501F. Representative of 3 repeat experiments 
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 3.3.3 SAMSN1 is a substrate of BLK and BLKR131W is unable to phosphorylate 
SAMSN1 
 
Proband C carries BANK1W40C allele and a rare heterozygous SAMSN1T198A variant 
(rs62227165). SAMSN1 has been implicated in the negative regulation of BCR signalling 
[327] as Samsn1-/- mice have enhanced B responses and impaired repression of Lyn 
activation [327], a Src family member critical in BCR and BANK1 signalling [328]. We 
therefore hypothesized that a SAMSN1 loss-of-function mutation would compound BANK1-
associated changes to B cell responses through changes in Src family signalling. The T198 
residue resides in an SH3 domain and may be necessary to stabilize the conformation of the 
SAMSN1 n-Src loop (Fig. 15). We tested whether the SAMSN1T198A variant altered the ability 
of SAMSN1 to repress Lyn activation. SAMSN1T198A did not change LYN phosphorylation 
(Fig. 16). Given the absence of data regarding the function of SAMSN1, we therefore could 
not observe a functional effect of the SAMSN1T198A variant. However, we found that LYN was 
capable of phosphorylating SAMSN1 by co-expressing an SDM-generated constitutively 
active version of LYN, LYNY501F, with SAMSN1WT (Fig. 17). The Src-family kinases LYN, BLK 
and LCK are known to share several substrates. We thus hypothesized that BLK would also 
be capable of phosphorylating SAMSN1. Indeed, co-expression of BLK and SAMSN1 in 
HEK239T cells revealed that SAMSN1 is also a substrate of BLK (Fig 18).  We then tested 
whether BLKR131Wwould, as with BANK1, be unable to phosphorylate SAMSN1. As 
predicted, when co-expressed, BLKR131W was unable to phosphorylate SAMSN1 (Fig 18). 
Although the consequence of the SAMSN1T198A variant on normal SAMSN1 function is 
unclear, these results identify SAMSN1 as a novel substrate of Lyn and BLK and 
demonstrate that the BLKR131W variant disrupts this interaction. Therefore, SAMSN1 is 
involved in the post-BCR BLK signalling pathway. 
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Figure 15. Structure of the wild-type SAMSN1 SH3 domain (PDB 2KEA) shown with a bound 
ligand modelled (from PDB 1CKA). Threonine 198 (shown in white stick representation) is 
located on the n-Src loop. Residues at the distal end of this loop form part of the ligand-
binding pocket in a number of SH3 domains. Modelled by J. Babon. 
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Figure 16. α-phosphotyrosine blot of Lyn co-transfected with SAMSN1WT or SAMSN1T198A. 
Lyn was cotransfected in HEK293Ts with indicated SAMSN1 genotype and Lyn was 
precipitated 48 hours after transfection. There is no appreciable difference in Lyn 
phosphorylation in the presence of SAMSN1WT or SAMSN1T198A. Representative of 3 repeat 
experiments. 
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Figure 17.  α-phosphotyrosine blotting of SAMSN1 immunoprecipitated 48 hours after 
cotransfection of HEK293Ts with LYN. Precipitated LYN is phosphorylated by SAMSN1 
demonstrating that SAMSN1 is a substrate of LYN. Representative of 3 repeat experiments 
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Figure 18. α-phosphotyrosine blotting of immunoprecipitated SAMSN1 after co-transfection 
with BLKWT or BLKR131W. 2ug of BLK and SAMSN1 were transfected in HEK293Ts and cells 
were lysed at 48hours. SAMSN1 was immunoprecipitated and probed with α-
phosphotyrosine demonstrating that SAMSN1 is a substrate of BLK and BLKR131W is unable 
to phosphorylate SAMSN1. Representative of 2 repeat experiments 
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3.3.4 BANK1W40C alters cellular localisation 
 
BANK1 is known to localize with BLK and exon 2 deletions alter BANK1 localization 
in the cytoplasm [299]. Transfection of HEK293 cells with BANKWT or BANK1W40C in the 
presence of TRAF6 revealed that both BANK1WT and BANK1W40C accumulated in large 
intracytoplasmic aggregates (Fig. 19) but these aggregates were significantly decreased in 
BANK1W40C transfected cells (Fig. 20). These aggregates were found to be p62+ 
sequestrosomes (Fig. 21) and contain TRAF6, thought to be inactive in these compartments. 
It is thus possible that these sequestrosomes also contain inactive forms of BANK1, given 
that for BANK1 to be active it needs to localize in proximity to the membrane where the 
Src/BANK1 signalosome forms [299]. Furthermore, an important role of BANK1 may be to 
sequester TRAF6 in these compartments, upon certain types of BCR/TLR signalling or in 
cells during particular stages of development. 
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Figure 19.  Representative blots of intracellular localization of BANK1WT and BANK1W40C 
assessed blind to genotype at  72hrs after cotransfection with TRAF6 into HEK293T cells 
demonstrating vesicle formation or cytoplasmic patterns, respectively (Performed by V. 
Athanasopoulos). Representative of 3 repeat experiments 
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Figure 20. Quantification of cytoplasmic vesicle formation in HEK293T transfected with 3ug 
of BANK1WT or BANK1W40C DNA. Measurement of vescicles was performed blind to 
genotype at 72hours after transfection. Performed by V. Athansopoulos. Date representative 
of 3 separate experiments. P<0.001. 
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Figure 21.  Representative images of intracellular colocalization of BANK1WT with TRAF6 
and p62 in cotransfected HEK293T cells (Performed by V. Athanasopoulos) Representative 
of 2 repeat experiments. 
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3.4 Rare gene variants alter cellular physiology 
 
3.4.1 PBMCs from the BANK1W40C SLE patients have unique transcriptome 
 
To gain insight into the effect of the BANK1W40C SNV on global leukocyte function, we 
performed transcriptome analysis of peripheral blood mononuclear cells (PBMCs) from the 
probands. Frozen PBMCs were sent to collaborators in the laboratory of V. Pascual, Baylor 
Medical Institute, U.S., who performed RNA microarrays and analysed transcriptomes with 
reference to a large cohort of unselected paediatric and adult SLE patients (Fig. 22 and Fig 
23). Strikingly, PBMCS from BANK1W40C patients were notable for the absence of type-1 
interferon signatures (Fig. 23). Interestingly, genes that were prominently associated with 
probands with BANK1W40C correlated with plasma cell signatures suggesting a contribution of 
the variant to increased plasma cell responses. An important caveat to this observation is 
that the PBMCs from both the referent SLE cohort were not analysed and differences in 
lymphocyte frequency and treatment responses may affect the transcriptome response. 
Prominent type-1 interferon signatures are characteristic of the majority of SLE patients[329] 
(Fig. 24). RNA analysis demonstrated significant upregulation of IL-6, IL-10 and genes 
regulated by NF-kB (Fig. 25). 
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Figure 22. Identification of three type-1 IFN response modules (i= M1.2; ii= M3.4; iii = 
M5.12 Supp.) in transcriptomes from unselected SLE patients. The top figure indicates the 
designed map which groups gene profiles into patterns of indicated cellular 
responses/functions. The bottom figure represents an example of the gene expression map 
from an unselected SLE patient showing the common upregulation of IFN responses in red. 
(Blood Module Functional Map designed and provided by V. Pascual) 
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Figure 23. Expression of three type-1 IFN response modules identified in Figure 22 
(i= M1.2; ii= M3.4; iii = M5.12.) are  abundant in a large majority of early onset SLE patients 
compared with PBMCs from BANK1W40C probands B and C. (Performed by V. Pascual) 
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Figure 24. Hierarchical cluster analysis of type-1 IFN genes demonstrates downregulation of 
type-1 IFN responses in BANK1W40C probands’ PBMCs global transcriptome profile and 
indentification of a cluster of upregulated genes associated with plasma blast reponses 
common to BANK1W40C probands. (Performed by V. Pascual) 
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Figure 25. Upregulation of NF-κB-associated genes in BANKW40C PBMCs compared with unselected SLE patients and heathly controls. 
(Performed by V. Pascual)
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3.4.2 Rare variants lead to increased IL-6 and IL-10 production 
 
In order to investigate B cell-autonomous effects of the mutations, lymphoblastoid B 
cell lines (LCLs) were generated from PBMCs from probands A, B and C and from healthy 
controls by collaborators in the laboratory of R. Khanna, Queensland Institute of Medical 
Research, Australia. LCLs were derived from proband B cells given the initial difficulties 
obtaining blood from affected individuals and the differences in treatment between the 
probands. Persistent activation with EBV will result in consistent non-canonical NFkB 
activation and the potential to therefore enhance and TLR response. Given the actions of 
BANK1 and IRAK2 in TLR signalling and SAMSN1 and BLK in BCR signalling, we tested the 
effect of TLR7/8, TLR9 and BCR stimulation on IL-6 production, since this cytokine had 
previously been shown to be regulated by BANK1[320] and the probands with the 
BANK1W40C variant had increased IL-6 mRNA levels (Fig 25). All LCLs derived from 
probands carrying the BANK1W40C SNV had significantly increased IL-6 production at 72 
hours after stimulation with TLR7/8 agonist R848, a trend to increased IL-6 production after 
TLR9 agonist CpG, but not with LPS or BCR stimulation (Fig. 26). These LCLs also showed 
a trend towards higher IL-10 production (Fig. 26). IL-6 and IL-10 contribute to plasma cell 
differentiation and both cytokines have been found to be elevated in the serum of SLE 
patients[330].  
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Figure 26. IL-6 (a) and IL-10 (b) secretion by 2.5x 105 LCLs derived from BANK1W40C 
probands compared with healthy controls 72 hours after stimulation with R848. Each point 
represents LCLs derived from a single BANK1 proband. Representive of 3 replicated 
experiments. *=p<0.05 
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TLR-ligation results in NF-κB expression and production of proinflammatory 
cytokines including IL-6. Both identified mutations in IRAK2 are gain of function variants and 
the proband PBMCs exhibited elevated levels of IL-6 mRNA transcription. Therefore, we 
hypothesized that the IRAK2 mutations would enhance TLR-mediated IL-6 production similar 
to that observed in the LCLs. HEK293T cells expressing TLR9 were transfected with wild 
type IRAK2, IRAK2S47Y and IRAK2T508M and stimulated with CpG. As expected, at 72 hours 
post stimulation IL-6 production was increased by both variants compared with wild type 
IRAK2 (Fig. 27).  
 
Next we tested whether the SAMSN1 SNV could contribute to the TLR mediated IL-6 
and IL-10 response observed in the probands’ LCLs. For this, we introduced the 
heterozygous SAMSN1T198A variant into the Ramos cell lines using CRISPR-Cas9 DNA 
editing. Surprisingly, this SAMSN1T198A/+ B cell line exhibited a significant increase in IL-10 
production in response to CpG stimulation, but not R848 (Fig. 28). Thus, SAMSN1T198A/+ 
confers a selective increased IL-10 response to CpG stimulation. 
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Figure 27. IL-6 production is increased in TLR9-expressing HEK293Ts transfected with 
IRAK2 variants. 2.5 x 105 HEK293Ts were transfected with indicated plasmids and 24 hours 
later stimulated with CpG. Supernatant was collect 48 hours post transfection. 
Representative of 2 separate experiments.  
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Figure 28. IL-10 production by CRISPR-Cas9 engineered SAMSN1T198A/+ or WT human B 
cells (Ramos) 72 hours after CpG and R848 stimulation. Representative of 2 repeat 
experiments. ***=p<0.001 
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3.5 Mice with synonymous human rare variants develop lupus 
 
To test the in vivo effects of the BANK1, BLK and SAMSN1 variants, we created 
C57BL/6 mice bearing the BANK1W40C, BLKR131W and SAMSN1T198A variants using CRISPR-
Cas9 editing. Immunophenotyping of these mouse strains revealed no differences in B or T 
cell subsets (Fig. 29). 
 
We next investigated the presence of antinuclear antibodies (ANAs). Strikingly, 
serum from 16 week old BANK1W40C/+, SAMSN1T198A/+, and BANK1W40C/+BLKR131W/+ mice 
contained anti-nuclear antibodies (ANAs) whereas serum from WT littermates did not (Fig. 
30). Kidneys from the BANK1W40C/+ and BANK1W40C/+BLKR131W/+ CRISPR-Cas9 engineered 
mice also were tested by I. Papa, JCSMR, ANU, for nephritis and exhibited IgG and IgA 
deposition (Fig. 31). Taken together, generation of orthologous SNV in mice demonstrates 
that the rare heterozygous mutations found in human SLE patients induce abnormal B cell 
responses similar to those observed in patient-derived B cells and also cause end-organ 
(kidney) involvement. 
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Figure 29. Phenotyping of splenocyte B cell populations in 2 month old WT and Bank1+/W40C 
mice. Performed by M Yabas. Data representative of 2 separate experiments. 
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Figure 30. Antinuclear antibodies (ANAs) determined by Hep-2 immunofluorescence at a 
serum dilution of 1:40 from 16 week-old Bank1W40C/+, Bank1W40C/+BlkR131W/+  and 
Samsn1T198A/+ mice compared to wildtype littermate controls as indicated. Representative of 
4 mice for each, except for Bank Performed by I. Papa. 
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Figure 31. IgG and IgA deposition in renal glomeruli from 16 week-old Bank1W40C/+ and 
Bank1W40C/+BlkR131W/+ determined by direct immunofluorescence of frozen kidney sections. 
Representative of 3 Bank1W40C/+ mice and 2 Bank1W40C/+BlkR131W/+ .  Performed by I. Papa 
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4.1 Copy Number Variation in Vangl1 associates with nephritis in SLE 
 
To determine the role of CNV in SLE, the Vinuesa lab undertook Comparative 
genomic hybridisation (CGH) using Affymetrix 5.0 SNP chip arrays in a small cohort of SLE 
patients (n=55) and healthy controls (n=11). The Affymetrix 5.0 array has ~500,000 SNP 
probes and ~420,000 CNV probes which allow for a locus-by-locus measure of CNV. Array 
data was analysed using R statistical language package CRNA[331] by M. Bahlo and A. 
Moldovan. All 66 arrays passed QC checks. After filtering a total of 982 CNVs were retained 
for all 66 samples. Several CNVs were detected in more than one individual by Sevcan 
Mercan, including three individuals whose CNVs covered VANGL1. Sevcan validated these 
CNVs by real-time using Taqman probes designed at the CNV site, and examined them in 
the larger APOSLE cohort. In this larger validation study only the association between the 
CNV within VANGL1 and SLE nephritis was found to be statistically significant (x2=24.2, 
p=<0.0001). Importantly, this association occurred specifically between zero copies or a 
double deletion of the VANGL1 CNV and SLE nephritis, but not SLE in general. The initial 
array analysis suggested all three SLE patients had the same double deletion of an 
estimated 3.17 kb of this gene spanning chr1:116,030,911-116,034,081 (NCBI36/hg18 
assembly), within intron 8. This finding was supported by only two SNPs on the array, given 
the small size of the CNV. To confirm these findings Sevcan performed qPCR targeting the 
CNV region identified in intron 8 of VANGL1 in a larger cohort of SLE patients (n=315) (Fig 
32). This assay replicated the association of CNV with SLE nephritis as well as the frequent 
occurrence of the CNV in this cohort. Furthermore, the correlation between 0, 1 and 2 or 
more Vangl1 copies implied a gene-dose protective effect for Vangl1. The qPCR was 
repeated in a large Portuguese (n=605) cohort reproducing the correlation between CNV in 
Vangl1 and nephritis in SLE patients, albeit to a lower magnitude (Fig 33). Odds ratio for 
nephritis comparing 0 CNV versus 1 or more CNV was 1.37 (95%Ci 0.87-2.19). The 
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Portuguese cohort comprised unselected SLE patients recruited by collaborator M. Alarcon-
Riquelme as part of the BioLUPUS consortium.  
 
To determine the size of CNV we performed whole genome sequencing in patients 
with SLE nephritis and identified CNV of variable size in different patients (Fig 34). Public 
databases report a relatively common occurrence of this CNV in intron 7 of VANGL1 (Fig 35) 
and high expression of this gene in human CD34+ and CD105+ cells, which may include 
endothelial cells, T cells and monocytes[332].   
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Figure 32. Association of CNV in VANGL1 with SLE nephritis. (p=<0.0001) 
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Figure 33. Replication of association with SLE nephritis in a Portuguese cohort (p=0.04). 
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Fig 34. Whole genome sequencing of randomly selected patients with SLE nephritis 
demonstrates CNV in intron 7. The presence of nephritis is identified by treating physicians. 
Each peak represents a series of unique sequences generated during WGS. The relative 
heights of the reads indicates coverage of a given region. Deletion of this region can be 
confirmed by relative coverage within the deleted are compared to coverage in surrounding 
region. 
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Figure 35. Schematic of CNV deletions inVANGL1. (Database of Genomic Variants) 
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Intronic deletions may cause alterations in splicing or removal of transcription 
enhancer elements. 4 protein coding splice variants are known to exist, although it unknown 
if these splicing variants have differential organ expression. I first tested if this CNV altered 
splicing by sequencing full length cDNA generated from blood from healthy controls vs 0 
CNV donors. Sanger sequencing of cDNA from patients with 0 CNV revealed normal full 
length transcripts of VANGL1. We next asked whether the CNV influenced VANGL1 
expression in PBMCs from SLE patients. For this, we performed qPCR on PBMCs from SLE 
patients with or without the CNV but found no difference in VANGL1 expression between 
those that had been identified with 0 CNV and 2 CNV (Fig. 36). Furthermore, there was no 
observable difference between healthy controls and SLE patients with or without nephritis 
(Fig. 36) although limited numbers of patients makes false negatives possible. Therefore, 
CNV in VANGL1 is associated with the predisposition to nephritis in SLE patients, but does 
not alter gene expression in PBMCs. A remaining possibility is that kidney specific 
expression or splicing is affected, but this could not be tested due to lack of biological 
resources. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Copy number variation in Vangl1 and lupus nephritis 
111 
 
 
 
 
 
 
 
 
Figure 36. Differences in mRNA expression of VANGL1 in PBMCs comparing SLE patients 
with or without 0 CNV or comparing those with or without nephritis. Healthy controls n=5, 
SLE nephritis n=3, SLE without nephritis n=5. 2 CNV n=4, 0 CNV n=3. Each point 
represents one individual. 
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4.2 Vangl1+/- mice develop spontaneous deposition of immunoglobulin in the kidney 
 
Vangl1 paralog Vangl2-deficient mice have reduced glomerular numbers and 
impaired kidney morphogenesis. Recent work demonstrated a role for Vangl2 in directing 
podocyte repair and genetic deficiency was associated with impaired recovery after acute 
glomerular injury and a predisposition to focal segmental glomerulosclerosis[333].  We 
hypothesised that given the important role of Vangl2 in kidney development and repair, 
Vangl1 CNV may play overlapping roles and also predispose to SLE nephritis in a kidney-
intrinsic manner.  Using immunohistochemistry we stained kidney sections from 10 week old 
adult C57/B6 mice. Similar to the observations made on Vangl2, Vangl1 was detected 
largely within tubules but not within the glomeruli (Fig. 37). This likely represents the 
transient glomerular expression of Vangl1 during development and repair. To determine if 
Vangl1 had a prominent role in glomerular development, akin to Vangl2, we stained sections 
of D18 foetal kidneys but did not detect Vangl1 in the glomeruli of these sections although it 
was detected in neural tissue, as expected (Fig 38). 
 
To test the consequences of Vangl1 deficiency in vivo we obtained mice with 
targeted frameshift null allele from exon 4 of Vangl1 (KOMP repository) and found Vangl1-/- 
mice were embryonic lethal between D15 and D18 due to neural tube defects (Fig. 37). We 
examined kidneys from Vangl1+/- mice and observed they developed spontaneous 
deposition of IgA and IgG (Fig. 39), but not IgM, C3 or C4, within the glomeruli. Interestingly, 
despite universal immunoglobulin (Ig) deposition (performed by I. Papa) observed by 
immunoflourescence, by light microscopy Vangl1+/- glomeruli were normal (Fig 41). 
Nevertheless, electron microscopy performed by M. Koina (The Canberra Hospital 
Pathology Department) demonstrated significant deposition within, and mild expansion of, 
the mesangium in addition to cast-like material within the tubules (Fig 42). To ascertain the 
clinical consequences of Ig deposition, serum creatinine and proteinuria were measured at 6 
and 9 months of age and no difference between wild-type or Vangl1+/- mice was detected 
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(Fig 43). Therefore, Vangl1+/- mice have spontaneous mesangial deposition of Ig with no 
evidence of inflammation or kidney function impairment. 
 
3.8 Vangl1+/- immunoglobulin deposition occurs in a kidney intrinsic manner 
 
To determine the potential source of immunoglobulin deposition, we first asked 
whether antibody deposition it was associated with increased systemic production of Ig or 
was a manifestation of systemic autoimmunity. Flow cytometric examination of Vangl1+/- 
mouse splenocytes did not demonstrate significant differences in lymphocyte populations, 
including all B cell subsets (Fig 44). At 20 weeks of age there was no evidence of 
autoimmunity as measured by ANAs (Fig 45) or difference in any class of Ig produced by 
Vangl1+/- mice (Fig. 46). 
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Fig 37. Staining of 3 month old WT mouse kidneys demonstrate Vangl1 expression in 
tubules. Brown= Vangl1. Representative of 4 mice. 
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38. Staining for Vangl1 in kidneys obtained from D18 WT mouse foetus 
demonstrates no Vangl1 expression. Brown= Vangl1. Representative of 4 mice. 
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Figure 39. H&E stains of neural tube defects found in D15 Vangl1-/- mouse foetus. 
Representative of 2 homozygous foetuses. 
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Figure 40. Immunoflourescence detecting trace IgA and IgG in 2 month old Vangl+/- 
and Vangl1+/+ mice. Representative of 5 mice per group. Representative of 3 repeat 
experiments 
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Figure 41. Light microscopy of glomeruli in Vangl+/- and Vangl1+/+ mice, aged 2 
months. Representative of 5 mice per group. 
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Figure 42. Electron microscopy of Vangl+/- and Vangl1+/+ mice kidneys aged 2 
months. Red arrows indicate electron dense deposits in the mesangium. (By M. Koina) 
Representative of 3 mice per group. 
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Figure 43. Serum creatinine from 3 month old Vangl+/- and Vangl1+/+ mice shows no 
significant difference. 
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Fig 44. Flow cytometry gating strategy and comparison demonstrates normal B cell 
populations in 3 month old  Vangl1+/- mice. 3 mice per group. 
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Figure 45. Antinuclear antibodies from 20 week old Vangl+/- and Vangl1+/+ mice 
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Fig 46. Serum Immunoglobulin levels from 20 week old Vangl+/- and Vangl1+/+ mice 
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In view of no evidence of increased systemic production of Ig, the known role of 
Vangl2 in the kidney morphogenesis and podocyte repair, as well as our demonstration of 
Vangl1 expression in the kidney, we hypothesised that Ig deposition in the kidney in 
Vangl1+/- is due to kidney-intrinsic predisposition to Ig deposition. To test this, we crossed 
Vangl1+/- mice to CD79aken/ken mice that lack mature B cells and thus circulating Ig [334]. 
Serum from age- and sex-matched Vangl1+/- or Vangl1+/+ mice was injected daily for 5 days 
into either Vangl1+/-CD79aken/ken or Vangl1+/+CD79aken/ken mice. On day 6, the four groups of 
mice were sacrificed and kidneys were examined for Ig deposition. Serum from either 
Vangl1+/- or Vangl1+/+ mice was deposited in Vangl1+/-CD79aken/ken mice whereas 
Vangl1+/+CD79aken/ken mice were resistant to IgG deposition regardless of whether the serum 
came from Vangl1+/- or Vangl1+/+ mice (Fig 47). This result demonstrates that susceptibility to 
Ig deposition in Vangl1+/- is kidney-intrinsic and excludes qualitative abnormalities in 
Vangl1+/- IgG causing Ig deposition. IgA was not detected in any recipient kidneys, likely due 
to a sensitivity issue (too low circulating IgA to achieve sufficient levels and deposition in 
recipients). To determine the effect of an autoimmune background on Vangl1 deficiency, we 
crossed the Vangl1+/- mice to Faslpr mice and measured serum creatinine and albuminuria as 
a marker of nephritis. However, across all time points no significant difference between the 
Vangl1+/- and Faslpr Vangl1+/- mice was detected (Fig 48 and Fig 49) suggesting that on the 
Faslpr background Vangl1 deficiency did not exacerbate nephritis. All experiments with the 
exception of the two CNV arrays, electron microscopy, and immunoflourescence were 
performed by myself. 
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Figure 47. Immunoflourescence of IgG in B cell deficient Vangl+/- and Vangl1+/+ mice injected 
daily with 100ul of mouse serum for 5 days. Representative of 3 mice per group. 
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Figure 48. Creatinine measurements of 4 month old Vangl1+/- Fas.lpr mice. No significant 
differences observed between genotypes. 
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Fig 49.  Albumin:creatinine ratios for Faslpr+/- Vangl1 mice of indicated age.
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5.1 Overview 
 
This thesis demonstrates several mechanisms through which genetic variation 
predisposes towards complex autoimmunity. Firstly, it provides evidence for how complex 
disease can be dissected using WES, identifying rare and novel genetic variants and, based 
on analysis of their epistatic interactions, their functional consequences. Whereas the 
prevailing hypothesis suggests that genetic risk in SLE and other complex autoimmune 
diseases is the result of a multitude of common, weak variants combining to break tolerance, 
this thesis demonstrates that single mutations in the heterozygous state have the capacity to 
induce autoimmunity. Specifically, this thesis demonstrates how variants in the proximal B 
cell signalling pathway and endosomal TLR pathway can disrupt B cell physiology and 
contribute to SLE.  
 
The second part of this thesis provides evidence for genetic mechanisms that 
predispose towards organ involvement. It reports the contribution of a CNV in VANGL1, 
specifically a large deletion in intron 7, towards nephritis in SLE. Although particular 
autoantibodies have been associated with organ specificity, such as with anti-smith and anti-
double stranded DNA antibodies and their association with nephritis in SLE, to date no 
organ-intrinsic mechanisms have been identified. Vangl1, expressed during mouse kidney 
organogenesis, suggests that a kidney-intrinsic defect that likely occurs during development 
predisposes to autoimmunity. We therefore add to the growing evidence of the importance of 
CNV in human disease. This thesis provides evidence for how organ-intrinsic defects may 
predispose to their involvement in disease. 
 
Together, this work makes several novel contributions to the genetic theory of SLE. 
First, this thesis demonstrates that rare genetic variants can strongly predispose or overtly 
induce autoimmunity. Second, that by scoring these variants and identifying similar gene 
expression profiles or similar phenotypes in gene knockout models we can identify and test 
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novel interactions. In this fashion, WES and WGS in complex autoimmune diseases can be 
a vehicle for immune gene function discovery similar to ethyl-nitrosurea mutagenesis 
programs. Thirdly, this thesis suggests that rare variants may explain a proportion of the 
genetic risk unidentified to date and may also confer some of the risk haplotypes identified 
by GWAS. Finally, it is the first demonstration to date of how structural variants in genes 
expressed in end-organs may explain or influence organ damage in complex autoimmunity 
with implications for treatment and transplantation.  
 
5.2 Contribution of BANK1W40C 
 
This study proposes a method by which bioinformatic data from diverse public 
databases can be aggregated to select out variants of low interest and therefore enrich for 
SNV that may contribute to SLE pathogenesis. In initial pedigrees BANK1W40C is identified as 
a critical variant underlying genetic risk in a minority (2-6%) of SLE patients. Identification of 
BANK1W40C as a core risk variant led to the identification of several possible interacting 
mutations. Interestingly, when determining the prevalence of BLKR131W and IRAK2S47Y 
variants identified by WES, unlike the BANK1W40C, these were not observed at higher 
frequencies. This suggests that although these variants contribute to SLE pathogenesis as 
demonstrated by this work, BANK1W40C appears to play a more central role. BANK1W40C was 
found at significantly higher rates in our APOSLE cohort compared to dbSNP reported 
frequencies. Interestingly, BANK1W40C has been reported in all racial backgrounds except 
those of Asian descent. None of our probands were of Asian descent, and given a significant 
proportion of the screened APOSLE cohort are of Asian descent, the risk of developing SLE 
associated with BANK1W40C may be higher in cohorts of European or European-American 
ancestry. Performing exome sequencing on a group of SLE individuals carrying the 
BANK1W40C variant, the scoring algorithm identified secondary mutations likely to contribute 
to disease. In addition to bioinformatic variables that suggested these second mutations in 
SAMSN1, BLK, and IRAK2 could be important interactors, the reported murine phenotypes 
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from the respective models of knockout suggested they may interact with BANK1 on a 
physiological level. Through further evaluation of these mutations, this study then discovers 
several novel interactions amongst the identified variants (SAMSN1 and BLK) and between 
some variants (i.e. IRAK2) and BANK1. Thus, BANK1 therefore unifies otherwise apparently 
unrelated genes and their variants. 
 
The natural function of BANK1 remains unclear, yet it can be hypothesised that 
BANK1W40C is the central variant due to its function as a scaffolding protein that facilitates 
interaction between BCR and TLR signalling proteins. As a central scaffolding protein, 
bringing interacting partners in proximity to each other, it is conceptually vulnerable to 
mutations disrupting multiple pathways, i.e. TLR, BCR, and co-stimulatory paths such as 
CD40. This observation makes BANK1 a strong candidate as a central player in 
autoimmunity as previous work has demonstrated how anergy relies on uncoupling BCR and 
TLR signals [128]. We clearly link BANK1 to both the BCR and TLR signalling pathways, yet 
how BANK1 can influence these two pathways to repress autoimmunity requires further 
investigation. Our demonstration that BANK1 over-expresison induces formation of p62+ 
sequestrosomes containing TRAF6 suggests this may be a mechanism by which BANK1 
can turn off NF-B signals in B cells upon BCR+/- TLR signals. The ability to sequester 
TRAF6 may extend to other TRAF family members including NF-kB inhibitory TRAF family 
members such as TRAF3, known to inhibit NF-kB-mediated IL-10 and IL-6 production and B 
cell survival downstream of BAFF-R stimulation [335]. 
 
5.3 Contribution of BLKR131W 
 
Both Src family members LYN and BLK have been repeatedly implicated in 
development of SLE and autoimmunity in general by GWAS [298,336]. Similar to the 
circumstances of BANK1, the haplotype implicated by the GWAS identified variant in the 
C8orf13-BLK intergenic region may include the rare variant BLKR131W [298]. This may 
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therefore also support the hypothesis that common variants used by GWAS studies detect 
rare deleterious mutations within areas of linkage disequilibrium. A further similarity between 
BLK and BANK1 is their GWAS association in several antibody-mediated and genetically 
complex autoimmune diseases such as rheumatoid arthritis and systemic sclerosis [337-
339] suggesting a contribution to autoimmunity in general and not just SLE. 
 
Several Src family members exist in B cells, Lyn, Fyn, Blk, and Src. There appears to 
be a relative hierarchy of importance amongst these family members, as Lyn deficient mice 
have clear B cell and T cell abnormalities which result in a SLE-like phenotype [340]. Both 
Fyn and Src deficiency appear to have mild autoimmune phenotypes with predominantly 
kidney involvement[341], and combined Src-family member deficient mice have phenotypes 
more exaggerated than single Src-member deficient mice [341]. Blk-/- mice were reported to 
have only a modestly abnormal immunophenotype [342] attributed to redundancy with other 
Src family members, although this has recently been challenged [343]. Arginine residues 
within the SH2 domains of all Src family members interact with phosphorylated C-terminal 
tyrosine residues. The interaction between different arginine-tyrosine pairs results in the Src 
protein to adopt either a closed or open conformation. In the open conformation, the kinase 
domain is exposed that permits substrate phosphorylation whereas in closed conformations 
this kinase domain is concealed. In the case of BLK, BANK1 is one such substrate and the 
BLKR131W variant, due to loss of the arginine required to hold BLK in an open conformation, 
has a virtually abolished ability to phosphorylate BANK1, a known requirement for BANK1 to 
interact with partners such as PLCG2 [299]. It is therefore unsurprising that the BANK1W40C/+ 
and BLKR131W/+ may have epistatic interactions. The question remains of how the kinase-
inactive BLK and its inability to phosphorylate BANK1 contributes to the development of 
autoimmunity. Given that we speculate mutant BANK1 does nto efficiently localise and 
perhaps direct TRAF proteins to p62+ sequestrosomes, it is possible that BLK-induced 
BANK1 phosphorylation is critical for this subcellular localization or TRAF-family interactions.  
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5.4 Contribution of IRAK2S47Y and IRAK2T508M 
 
The MyD88-associated IRAK family has been strongly implicated in autoimmunity 
and SLE. A common variant of IRAK1, which is a direct interactor with IRAK2, has been 
shown to segregate with SLE and mutations of IRAK1 cause autoimmunity in the sle1 
mouse model. IRAK1, along with IRAK2 and IRAK4, are recruited to MyD88 wherein IRAK 
members undergo extensive auto-phosphorylation. Activation within this complex leads to 
NF-κB activation through TRAF6. We found compound heterozygosity for IRAK2 in proband 
A, with both mutations exhibiting an enhanced capacity to interact with other IRAK members 
as well as TRAF6. This results in increased NF-kB-dependent transcripts and production of 
the proinflammatory cytokine IL-6. Elevated IL-6 is a common finding in SLE and other 
autoimmune diseases [330,344,345] and contributes to the TLR-mediated IL-6 production 
observed in the proband’s LCLs. Furthermore, the proband’s pedigree suggests the effect of 
the mutations may predispose to SLE in a dose dependent manner. 
 
IRAK2 is expressed in B cells. In mice, in which expression in well characterized in 
public databases, IRAK2 expression is high in follicular and marginal zone B cells, with low 
amounts expressed in germinal center B cells (http://www.immgen.org). Unlike BANK1 or 
Blk, the IRAK2 genes are also expressed in myeloid populations. Therefore, besides 
possible direct epistatic interaction with BANK1 in B cells IRAK2 may also contribute to the 
development of autoimmunity via myeloid cell dysregulation: Monocyte or pDC TLR 
stimulation in the presence of mutant IRAK2 may also lead to excessive NF-κB activation 
with commensurate increases in IL-6 production and antigen presentation. Myeloid-derived 
IL-6 production has been reported to be important in mediating autoimmunity associated with 
Lyn deficiency [346] and may similarly exacerbate BANK1W40C autoimmunity.  It is important 
to note that while every affected family member in pedigree A carried the BANK1 mutation, 
only 2/3 carried the IRAK2 allele, suggesting that in at least two patients this allele may 
exacerbate disease, but as shown in the case of the other two pedigrees, its presence is not 
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obligatory for SLE development in the presence of BANK1W40C. Genome sequencing of the 
younger family member that does not carry the IRAK mutation and has been recently 
diagnosed with Sjogren’s Sd at age 11 may reveal yet another hit in the BCR-TLR pathway. 
Assessing all pedigrees, a pattern emerges: BANK1W40C is sufficient to predispose to 
production of ANAs, but all individuals with a severe autoimmune syndrome in each of the 
pedigrees (APS, SLE, SS, RA) have a second rare damaging mutation in a BCR/TLR 
signalling gene.  
 
5.5 Contribution of SAMSN1T198A 
 
SAMSN1 is a recently described gene identified as a potential regulator of Lyn [327]. 
Although it has been implicated in BCR signalling as a repressor of Lyn, unlike other genes 
identified by this study it has not been associated with SLE. It was considered of particular 
interest as Samsn1-/- mouse B cells had increased proliferation and activation [327] 
reminiscent of the initial reports of the Bank1-/- mice and we hypothesised that deficiency of 
two genes which induce similar phenotypes of B cell hyperactivity may, even if functioning in 
independent pathways, result in additive or synergistic effects on B cell physiology.  
 
Whilst investigating the contribution of SAMSN1, we have made several novel 
observations. First, SAMSN1 is a novel substrate of BLK and Lyn, similar to BANK1. 
Whether it therefore has a role in negative feedback of Lyn is an area of further investigation. 
Second, SAMSN1 has a significant role in TLR9-mediated IL-10 responses. The high levels 
of IL-10 in SAMSN1T198A/+ Ramos cell lines in response to CpG stimulation is consistent with 
findings of elevated IL-10 in SLE patients and mouse models [211,330]. SAMSN1T198A/+ may 
therefore be an example of why elevated IL-10 may also be observed in healthy relatives of 
SLE patients, representing a partial predisposition to antibody-mediated autoimmune 
disease [347]. 
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Two important questions arise from the observations found with SAMSN1T198A. 
Firstly, what is the role of SAMSN1 in B cell physiology? Herein we have implicated it directly 
in both BCR signalling as well as TLR signalling. The novel discovery of SAMSN1 as a 
substrate of Src family members suggests it, like BANK1, may play a dual role or regulate 
the convergence or cross-talk between these two pathways. The second main question that 
presents is how SAMSN1 regulates CpG-induced IL-10 responses. Both will require further 
investigation.  
 
5.7 Unifed theory of polymorphisms identified in this thesis 
 
This thesis identifies BANK1W40C as a variant that forms the genetic basis of a subset 
of SLE patients. The natural role of BANK1, and the contribution of the BANK1W40C allele 
remains to be elucidated, yet this thesis implicates the central role of BANK1 between the 
other implicated SNVs. BANK1 appears to link both TLR and BCR signalling pathways; it 
and SAMSN1 are substrates of BLK which is activated in response to BCR crosslinking. 
However, BANK1 also interacts directly with IRAK2 and LCLs derived from the probands’ 
PBMCs have increased responses to endosomal TLR stimulation. The interaction between 
TLR and BCR signalling has been considered important in the maintenance of B cell anergy 
as exemplified in the HEL/TgHEL mouse model of B cell anergy, yet the mechanism linking 
these pathways is unclear. Here, I hypothesise that the BANK1 is a natural fulcrum between 
these two mechanisms of B cell activation and that the BANK1W40C mutation alters the ability 
of B cells to regulate these two responses. Therefore, loss or gain of function mutations in 
either of these pathways will skew B cell responses. Indeed based on the aggregate effects 
of these variants it would appear that the BANK1W40C mutations impair BCR signalling (loss 
of function BLK SNV) whilst promoting TLR responses (i.e. gain of function IRAK2 SNV). A 
summary of the proposed signalling pathway is represented in Figure 50. 
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Figure 50. Proposed unification of BANK1 signalling pathway and importance in B cell 
activation by BCR or TLR. 
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5.6 Implications for the genetic theory of SLE and the value of WES/WGS 
 
GWAS has identified a growing cohort of genes associated with SLE and other 
autoimmune diseases. These variants are by necessity relatively common and the majority 
of experimentally tested variants have not been shown to be significantly deleterious to 
protein function. In comparison, using WES to identify rare or novel variants under 
evolutionary pressure we have demonstrated that rare mutations that could not be identified 
by GWAS have potent deleterious effects. BANK1W40C, in our cohort, characterises a subset 
of SLE in non-Asian populations which, either alone, or when combined with a rare 
damaging mutation in an interacting partner, results in loss of B cell tolerance and 
contributes to complex autoimmunity. Further investigation about the existence of epistatic 
interactions between the gene variants identified in this thesis may provide deeper insights 
into the basis of SLE and complex autoimmunity. Our results demonstrate the ability for 
WES and WGS to identify causative mutations and forms the basis for personalising 
treatment for SLE. 
 
Of the two major theories for genetic risk in autoimmunity, the weak common variant 
hypothesis or potent rare variant hypothesis, it has been argued that the GWAS identified 
risk SNVs are not the variants which confer risk. Rather, the SNV in GWAS represent 
haplotypes containing rare, potent variants that confer risk. Thus, the association detected 
by GWAS may actually be that of rare variants in disequilibrium with the identified variant. 
Nevertheless, the opposite argument has also been made: A recent report in Nature 
concluded the contribution of rare variants to autoimmunity will be negligible, after failing to 
identify rare variants in 25 GWAS genes sequenced in 24 892 individuals with autoimmune 
disease and 17 019 healthy individuals [282]. Of note, SLE was not included amongst the 
autoimmune diseases, and neither BANK1 nor BLK were sequenced. To this debate on the 
genetic architecture of SLE, this thesis offers evidence supporting the idea of rare variants 
being the ‘risk signal’ identified by GWAS. Both BANK1W40C and BLKR131W have been 
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previously identified as risk alleles in both SLE and other complex autoimmune diseases. 
That these rare variants with demonstrated pathogenicity are in close genetic proximity to 
the identified variants supports this argument. However, it is not conclusive and also does 
not preclude an additional role of other uncommon or common variants in disease 
pathogenesis. Indeed, it is likely that some common variants do contribute to risk, although 
this risk is likely to be less than that conferred by rare or novel variants similar to those 
presented in this study. 
 
5.7 Implications for classification and treatment of SLE 
 
 In addition to the contribution to understanding the genetic architecture of complex 
autoimmunity, these findings have direct implications for SLE. First, a formal diagnosis of 
SLE is based on meeting 4 of the 11 American College of Rheumatology criteria [14]. 
However, it has been well characterised through the literature that the clinical manifestations 
and underlying pathogenic mechanisms of SLE are diverse. The majority of clinical trials, 
diagnostic and prognostic studies are therefore restricted by this definition of SLE. By 
identifying molecular mechanisms causing SLE we may therefore reclassify SLE not as a 
clinical syndrome, but potentially by the genetic lesions or leukocyte or mechanistic 
pathways affected (i.e DNA degradation, complement activation).  
 
 The natural progression to refining SLE from a clinical phenotype to a cellular/genetic 
classification is the ability to better target therapy. Current non-specific anti-proliferative 
therapy and general immunosuppressives such as corticosteroids have a high side effect 
profile and in many cases do not adequately control disease. As a model of a B cell-
mediated SLE, BANK1W40C-related SLE may be more susceptible to B cell depletion therapy 
such as rituximab, which is only used as salvage therapy for refractory lupus in current 
regimes. 
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5.8 VANGL1 and kidney damage 
 
Whilst SLE is classically associated with the capacity to involve most organs, we 
provide the first demonstration of genetic predisposition to involvement of a specific organ in 
SLE. VANGL1 and VANGL2 are important PCP genes that have been implicated in human 
neural tube defects [348], and Vangl2 in murine kidney development and repair responses to 
injury [333]. Although loss of Vangl2 in mouse models results in fatal neural tube defects, 
conditional loss of Vangl2 in podocytes results in impaired glomerular repair and greater 
injury. In several SLE cohorts we identified a CNV in intron 7 of VANGL1 which associates 
with nephritis in a gene-dose protective manner. Interestingly, the CNV identified does not 
represent a single deletion but several deletions of differing sizes in the kilobase range. 
 
To determine the contribution of VANGL1 CNV to nephritis we examined Vangl1+/- 
mice. Although not immediately comparable with the intronic CNV in the SLE cohorts, 
Vangl1 deficient mice permitted examination of the effect of disrupting Vangl1. Vangl1-
deficient mice developed spontaneous IgA and IgG deposition in their mesangium, but not 
IgM or complement deposits.  We hypothesise that this pattern of Ig deposition may be due 
to disturbed glomerular endothelial expression of Vangl1 permitting passive diffusion of 
immunoglobulin across the endothelium of glomerular capillaries. This hypothesis stems 
from public databases of gene expression suggesting Vangl1 is expressed in endothelial 
cells. This would explain why monomeric immunoglobulins IgA and IgG, but not pentameric 
IgM, are detected in the mesangium of Vangl1+/- mice. Consistent with this hypothesis and 
despite deposition of monomeric immunoglobulins, Vangl1+/- mice did not deposit 
complement or show any evidence of inflammation or glomerular injury. It is also likely that 
this is due to the deposited immunoglobulins not being auto-reactive. Generally, auto-
reactive antibodies such as those found in SLE are known to be effective at activating 
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complement due to their ability to form large antigen-antibody complexes (immune 
complexes, IC), and inducing an inflammatory reaction.  
 
We propose that the requirement for autoreactive antibody to cause pathology may 
prevent purifying selection of the relatively common CNV within Vangl1 from an evolutionary 
perspective. To specifically test this hypothesis, we crossed Vangl1 deficient mice onto a 
lupus-prone mouse model, the Faslpr mouse. Although the systemic autoimmunity in Faslpr/lpr 
mice appears to induce nephritis regardless of Vangl1 deficiency, possibly by overwhelming 
innate resistance kidney resistance to autoantibody deposition, there was a significant 
difference in renal function comparing Faslpr/+ Vangl1+/- and Faslpr/+ Vangl1+/+ at 12 weeks of 
age although WT littermates had creatinine measurements comparable to the Faslpr/+ 
Vangl1+/-. 
5.9 Implications for drug therapy and transplantation 
 Genetic predisposition to glomerulonephritis (GN) has important implications for the 
management of patients with autoimmune GN. The first is primary prevention: by identifying 
patients with CNV in VANGL1 who also have SLE, we may better predict onset and 
therefore intervene earlier in patients. Earlier detection and intervention will help minimise 
accumulation of kidney damage which adversely affects life quality and mortality. From a 
therapeutic perspective, genetic risk may impact on transplantation practices. Where 
traditionally live related donors are considered the gold standard for transplantation, in 
instances of genetic predisposition to GN due to 0 copies in the VANGL1 intron 7 CNV, it 
may be that live unrelated donors are superior to related donors who may also carry genetic 
predisposition to nephritis. 
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5.10 Limitations of this thesis 
  
 Although this thesis strongly implicates rare variants in the development of SLE, best 
characterised by the phenotypes observed in the mouse carrying CRISPR-Cas9 edited 
orthologues of the BANK1, BLK, and SAMSN1 human mutations, there are significant 
components to pathogenesis and the process of identifying variants which limit this study.  
 
 Coverage with either WES or WGS is imperfect with approximately a 10% and 5% 
respective false negative rate. It is thus possible that failure to cover genes will result in the 
inability to identify novel targets. Indeed, the scoring algorithm developed herein utilises 
imperfect tools such as Polyphen2 and known mouse phenotypes to identify probable 
targets. The weighting given to genes known to have a role in the immune system, while it 
can help identify obvious candidates, it is also a potential pitfall, as genes that may be 
important but who have no known function will therefore be missed. It should be noted 
however, than in establishing a method for proof of causation this was an accepted 
deficiency – to both discover novel functions (or functions of unknown genes) as well as their 
contribution to autoimmunity was beyond the scope of this exploratory work. Nevertheless, 
our lab has recently identified a novel gene that we predict causes SLE in a multiplex family, 
so it is not impossible to uncover such variants, particularly in large pedigrees. This is a 
process as a whole that will require continued development and refinement.   
 
 It is also well established that environmental, gender, epigenetic and infectious 
influences all predispose to the development of SLE. What this thesis proposes is that these 
rare variants strongly predispose but do not explain absolutely the pathogenesis of complex 
autoimmunity. Indeed, common variants may also still exert significant genetic risks and be 
in epistasis with rare coding variants as well as structural, non-coding, and epigenetic 
variants. The environmental influences likewise will modify the risks associated with these 
genetic variants. It is highly likely that as work to identify these variants increases, variants 
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with great epigenetic susceptibility will be identified as well as variants likely to have more 
fundamental deficits that will be highly penetrant. 
 
 In identifying and demonstrating the contribution of rare variants, this thesis does not 
entirely define the mechanisms through which these variants break tolerance. Although this 
thesis suggests a common pathway and relates the variants to each other, it does not 
explain how they combine to break B cell tolerance. That all the identified variants interact 
with each other suggests they represent a common pathway predisposing to autoimmunity. 
The newly generated mouse models will be invaluable in understanding lupus pathogenesis 
caused by the human mutations. 
 
 The Vangl1-/- mouse model used in this thesis does not recapitulate the 
VANGL1 CNV identified SLE patients and differ in fundamental ways: The gene-trapped 
knockout are embryonic lethal in the homozygous state due to neural tube defects whereas 
patients homozygous for the identified CNV are commonly observed. Data from the 
Database of Genomic Variants reports multiple deletions of varying size in intron 7 of 
VANGL1, but not in any other intron or exon. This suggests that VANGL1 tolerates deletions 
in intron 7, but not in any exon or other intron.  Therefore the intron 7 CNV found in SLE 
patients with nephritis may have a specific functional defect beyond gene knockout, 
potentially as loss of a kidney-specific gene promoter within the intron. It is also plausible 
that the differences observed between Vangl1 deficient mice and humans relate to differing 
functions of Vangl1 in neural and kidney tissue in mice compared with humans.   
Several important lines of further investigation follow from the identification of the 
CNV in VANGL1. It is unclear how intronic CNVs in VANGL1 translate to kidney-specific 
injury in the absence of neural tube defects. It is possible that different exon usage and 
therefore isoforms are expressed at the different tissues or during development. To date, the 
4-coding transcripts described for human VANGL1 appear to share the same pattern of 
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intron 7-splicing (Ensembl.org) but libraries of all alternatively spliced-variants expressed 
across different tissues are still incomplete. The relatively high frequency of CNVs in intron 7 
of VANGL1 would suggest limited selectivity against these CNVs, perhaps even balancing 
selection where the heterozygous deletion may confer some selective advantage for a 
hitherto unknown trait. Although many antibody-mediated kidney diseases can be associated 
with specific antibodies and epitopes, the kidney intrinsic defect from Vangl1 deficiency may 
predispose to any form of antibody-mediated kidney disease. The precise mechanism 
through which Vangl1 deficiency permits this antibody deposition in such a kidney-intrinsic 
manner requires further elucidation, but it is possibly related to the defective podocyte repair 
mechanism described for Vangl2 [333]. In summary, we have described how a common 
CNV in VANGL1 predisposes towards nephritis in a kidney-intrinsic manner. This offers 
novel insights into how SLE may develop predilection for specific tissues and highlights the 
emerging roles of VANGL1 and other PCP genes in kidney injury and repair. 
 
5.11 Future directions  
 
 
 
 5.11.1 How does BANK1W40C affect tolerance and its role in autoimmunity and B cell 
signalling 
 
 Identification of BANK1W40C as a central variant in the predisposition to SLE will form 
the basis of several lines of investigation. Linking BCR and TLR signalling implies it may 
have an important role in regulation of NF-κB in the manner reported by Rui [128]. The 
capacity to sequester TRAF6 into sequestersomes and the elevated IL-6 production 
observed implicates BANK1 in NF-κB signalling. Crossing the BANK1W40C strain with Cblb- 
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HyHel10Tg will allow testing of whether BCR stimulation with autoantigen is capable of 
repressing TLR9 mediated autoimmunity in the presence of BANK1W40C.  
 
 Extension of stimulation studies should be performed with controls of BANK1-/- B 
cells to determine the polarity of the variant. Breeding to BANK1W40C homozygosity and 
stimulation through BCR and TLR receptors with appropriate negative controls illustrate 
whether the variant is gain or loss of function. It would be useful to determine if the 
interaction with TRAF6 extends to other TRAF family members such as TRAF3. The BANK1 
variant will need to be crossed with all identified variants to determine if epistatic interactions 
occur and whether the autoimmune and cellular phenotype observed is altered by the 
second variant’s effect in BCR or TLR signalling.  
 
 5.11.2 What role does SAMSN1 in TLR and BCR signalling?  
 
 Similar to BANK1W40C, further exploration of the role of SAMSN1 will be crucial. 
Foremost will be to cross SAMSN1T198A to the BANK1W40C mice to determine potential 
epistatic interactions between the variants, both in autoimmune phenotype and B cell 
responses to BCR and TLR signalling. The nature of the interaction between LYN, BLK and 
SAMSN1 will require further exploration, determining if SAMSN1-/- mice or SAMSN1T198A 
mice have constitutive activation of LYN, and whether the SAV may alter the LYN-/- 
phenotype.  Replication of the CpG-mediated IL-10 phenotype observed in CRISPR-Cas9 
edited SAMSN1T198A Ramos cell lines will need to be replicated in the SAMSN1T198A murine 
B cells and the mechanisms of this specific response explored further. One potential 
explanation is that SAMSN1 may be a specific scavenging receptor for CpG as its 
expression profile with some similarity to that of DEC205, a scavenging receptor which may 
play a role in recognition and endocytosis of self-antigen and contribute to peripheral 
tolerance. Replication of TLR9 stimulation experiments in the SAMSN1T198A mice should be 
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performed alongside a SAMSN1-/- control to determine also the polarity of the SAMSN1T198A 
variant. 
 
 5.11.3 How does BLKR131W alter BCR signalling and does BLKR131W exert epistasis 
with BANK1W40C? 
 
 BLK-/- mice develop expanded MZ B cell populations and glomerulonephritis. This 
thesis demonstrates BLKR131W as a loss of function variant. The mechanism through which 
BLK deficiency contributes to B cell autoimmunity remains to be elucidated. Several 
hypothesis may explain these observations. BLK, in combination with other Src family 
members, alters BCR signalling and may fail to dampen autoantigen receptor engagement 
adequately, thereby causing impairing necessary signals for receptor editing, deletion or 
anergy. The MZ phenotype observed in Blk-/- mice supports the role of BCR signalling 
abnormalities. Its mechanism of action may also be mediated through impaired BANK1 
signalling as evidenced by reduced phosphorylation of BANK1 observed in this thesis. 
 
 5.11.4 How does deletion of VANGL1 result in immunoglobulin deposition? Does 
VANGL1 affect other antibody mediated kidney disease? 
 
 Although this thesis offers evidence supporting a kidney intrinsic mechanism of 
antibody deposition, the mechanism through which this occurs is unclear. Based on gene 
expression profiles suggesting expression of VANGL1 in vascular endothelium (CD34+ and 
CD105+ populations) and absence of a discernible peripheral autoimmune phenotype, it is 
possible that deficiency of VANGL1 results from abnormal development of endothelium 
permitting passage of antibodies into the kidney mesangium.  
 
 If the lesion represents a predisposition to immunoglobulin, it would then not 
necessarily represent a predisposition to SLE but to any antibody mediated kidney disease. 
Chapter 5: Discussion 
 
146 
 
Further lines of investigation would involve determining if the copy number variation is highly 
represented in other autoimmune glomerulonephritis conditions such as IgA nephropathy 
and membranous glomerulonephritis. Similarly, epidemiological data of transplantation 
outcomes, comparing recurrence of autoimmune glomerulonephritis between live unrelated 
and live related donors, may support a kidney intrinsic predisposition to nephritis. Such an 
observation would have significant transplant policy and treatment outcomes. 
 
5.12 Conclusion  
 
This thesis has used WES to identify rare gene variants in a pathways that links BCR 
with TLR signalling and can predispose to complex autoimmunity. This approach 
demonstrates how WES/WGS can provide novel insights into gene function and map novel 
pathways in human autoimmune disease. These findings support the hypothesis that 
complex autoimmunity may result from as little as one or two rare variants with strongly 
deleterious effects that act alone or together to alter B cell responses. This thesis also 
demonstrates that genetic mechanisms exist that may explain some of the organ-specificity 
in SLE.  
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